Literatur

S3-Leitlinie/NVL Unipolare Depression

2. Auflage, 2015. Version 5 – Druckversion (PDF ) | Kapitelübersicht | weitere Informationen

1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationales Programm für Versorgungs-Leitlinien. Methoden-Report 3. Auflage. 2007 [cited: 2016-09-14]. http://www.leitlinien.de/mdb/downloads/nvl/methodik/archiv/nvl-3aufl-vers1.1-llr.pdf.

2. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien. Methoden-Report Patientenbeteiligung Stand Januar 2007. 2007 [cited: 2016-09-14]. http://www.aezq.de/mdb/downloads/nvl/methodik/mr-aufl-2-patientenbeteiligung.pdf.

3. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Leitlinien-Clearingbericht "Depression" (ÄZQ Schriftenreihe - Band12). Niebüll: 2003 [cited: 2016-09-14]. http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe12.pdf.

4. Härter M, Bermejo I, Ollenschlager G, et al. Improving quality of care for depression: the German Action Programme for the implementation of evidence-based guidelines. Int J Qual Health Care 2006;18(2):113-9.

5. Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung, et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2010) 13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. 2002 [cited: 2016-09-16]. http://www.leitlinien.de/mdb/edocs/pdf/literatur/europaratmethdt.pdf.

6. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997;94(33):A-2154.

7. National Institute for Health and Clinical Excellence (NICE). The guidelines manual. 2007.

8. Dunham RB. Nominal Group Technique: A Users' guide. 1998 [cited: 2016-09-14]. http://www.sswm.info/sites/default/files/reference_attachments/DUNHAM%201998%20Nominal%20Group%20Technique%20-%20A%20Users'%20Guide.pdf.

9. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health technology assessment 1998;2(3):i-88.

10. Stinner B, Bauhofer A, Sitter H, et al. Nominaler Gruppenprozess als Konsensusinstrument zur Einschränkung der Therapieheterogenität in einer komplexen "outcome"-Studie. Intensivmed Notfallmed 2000;37(Suppl 2):30.

11. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53(4):849-57.

12. Wittchen HU, Müller N, Schmidtkunz B, et al. Erscheinungsformen, Häufigkeit und Versorgung von Depressionen. Ergebnisse des bundesweiten Gesundheitssurveys "Psychische Störungen". Fortschr Med 2000;Sonderheft I:4-9.

13. Murray CJ, Lopez AD. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.

14. Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006;367(9505):153-67.

15. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998;33(12):587-95.

16. Busch MA, Maske UE, Ryl L, et al. Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013;56(5-6):733-9.

17. Jacobi F, Höfler M, Strehle J, et al. Psychische Störungen in der Allgemeinbevölkerung - Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). Nervenarzt 2014;85(1):77-87.

18. Kahn LS, Halbreich U. The effect of estrogens on depression. In: Bergemann N, Riecher-Rössler A, editors. Estrogen effects in psychiatric disorders. Wien: Springer; 2005. p. 145-73.

19. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74(1):5-13.

20. Kühner C. Gender differences in unipolar depression: An update of epidemiological findings and possible explanations. Acta Psychiatr Scand 2003;108(3):163-74.

21. Bennett DS, Ambrosini PJ, Kudes D, et al. Gender differences in adolescent depression: do symptoms differ for boys and girls? J Affect Disord 2005;89(1-3):35-44.

22. Jacobi F, Wittchen HU, Holting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004;34(4):597-611.

23. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(1):8-19.

24. Kühner C. Warum leiden mehr Frauen unter Depression? In: Lautenbacher S, Güntürkün O, Hausmann M, editors. Gehirn und Geschlecht. Neurowissenschaft des kleinen Unterschieds zwischen Frau und Mann. Berlin: Springer; 2007. p. 331-50.

25. Kuehner C. Is it all depression? JAMA Psychiatry 2014;71(3):337.

26. Cepoiu M, McCusker J, Cole MG, et al. Recognition of depression by non-psychiatric physicians - a systematic literature review and meta-analysis. J Gen Intern Med 2008;23(1):25-36.

27. Marcus SM, Kerber KB, Rush AJ, et al. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry 2008;49(3):238-46.

28. Marcus SM, Young EA, Kerber KB, et al. Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005;87(2-3):141-50.

29. Eaton WW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008;65(5):513-20.

30. Silverstein B, Edwards T, Gamma A, et al. The role played by depression associated with somatic symptomatology in accounting for the gender difference in the prevalence of depression. Soc Psychiatry Psychiatr Epidemiol 2013;48(2):257-63.

31. Schuch JJ, Roest AM, Nolen WA, et al. Gender differences in major depressive disorder: results from the Netherlands study of depression and anxiety. J Affect Disord 2014;156:156-63.

32. Rutz W. Preventing suicide and premature death by education and treatment. J Affect Disord 2001;62(1-2):123-9.

33. Winkler D, Pjrek E, Kasper S. Anger attacks in depression - evidence for a male depressive syndrome. Psychother Psychosom Med 2005;74(5):303-7.

34. Benazzi F. Evidence for a male or instead for a female depression? Psychother Psychosom 2006;75(3):192.

35. Lewinsohn PM, Pettit JW, Joiner TE, Jr., et al. The symptomatic expression of major depressive disorder in adolescents and young adults. J Abnorm Psychol 2003;112(2):244-52.

36. Judd LL, Schettler PJ, Coryell W, et al. Overt irritability/anger in unipolar major depressive episodes: past and current characteristics and implications for long-term course. JAMA Psychiatry 2013;70(11):1171-80.

37. Perlis RH, Fraguas R, Fava M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry 2005;66(2):159-66.

38. Moller-Leimkuhler AM, Yucel M. Male depression in females? J Affect Disord 2010;121(1-2):22-9.

39. Martin LA, Neighbors HW, Griffith DM. The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication. JAMA Psychiatry 2013;70(10):1100-6.

40. Nolen-Hoeksema S, Girgus JS. The emergence of gender differences in depression during adolescence. Psychol Bull 1994;115(3):424-43.

41. Apter A. Adolescent suicide and attempted suicide. In: Wasserman D, editor. Suicide. An unnecessary death. Cambridge: Dunitz; 2001. p. 181-94.

42. Beekman AT, Kriegsman DM, Deeg DJ, et al. The association of physical health and depressive symptoms in the older population: age and sex differences. Soc Psychiatry Psychiatr Epidemiol 1995;30(1):32-8.

43. Wittchen HU, Lieb R, Wunderlich U, et al. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry 1999;60(Suppl 7):29-36.

44. Knäuper B, Wittchen HU. Diagnosing major depression in the elderly: evidence for response bias in standardized diagnostic interviews? J Psychiatr Res 1994;28(2):147-64.

45. Jacobi F, Klose F, Wittchen H. Psychische Störungen in der deutschen Allgemeinbevölkerung: Inanspruchnahme von Gesundheitsleistungen und Ausfalltage. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2004;47(8):736-44.

46. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. Jama 1996;276(4):293-9.

47. Essau CA. Epidemiologie. In: Essau CA, editor. Depression bei Kindern und Jugendlichen: psychologisches Grundlagenwissen. München: Reinhardt; 2002. p. 45-62.

48. Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000;59(2):119-26.

49. Hankin BL, Abramson LY, Moffitt TE, et al. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol 1998;107(1):128-40.

50. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996;35(11):1427-39.

51. Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychol Med 1998;28(1):109-26.

52. Ernst C. Epidemiologie depressiver Störungen im Alter. In: Radebold H, Hirsch RD, editors. Depressionen im Alter. Darmstadt: Steinkopff; 1997. p. 2-11.

53. de Jong-Meyer R, Hautzinger M, Kühner C, et al. Evidenzbasierte Leitlinien zur Psychotherapie Affektiver Störungen. Göttingen: Hogrefe; 2007.

54. Katon WJ, Lin E, Russo J, et al. Increased medical costs of a population-based sample of depressed elderly patients. Arch Gen Psychiatry 2003;60(9):897-903.

55. Härter M, Baumeister H, Bengel J. Psychische Störungen bei Patienten mit einer somatischen Erkrankung aus der medizinischen Rehabilitation. In: Härter M, Baumeister H, Bengel J, editors. Psychische Störungen bei körperlichen Erkrankungen. Berlin: Springer; 2007. p. 55-70.

56. Volkert J, Schulz H, Harter M, et al. The prevalence of mental disorders in older people in Western countries - a meta-analysis. Ageing Res Rev 2013;12(1):339-53.

57. Luppa M, Sikorski C, Luck T, et al. Age- and gender-specific prevalence of depression in latest-life - systematic review and meta-analysis. J Affect Disord 2012;136(3):212-21.

58. Department of Health and Human Services Administration on Aging. Older adults and mental health issues and opportunities. Washington, DC: Administration on Aging: Department of Health and Human Services; 2001.

59. Teresi J, Abrams R, Holmes D, et al. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol 2001;36(12):613-20.

60. Beekman AT, Geerlings SW, Deeg DJ, et al. The natural history of late-life depression: a 6-year prospective study in the community. Arch Gen Psychiatry 2002;59(7):605-11.

61. Jansson M, Gatz M, Berg S, et al. Gender differences in heritability of depressive symptoms in the elderly. Psychol Med 2004;34(3):2004.

62. Oslin DW, Datto CJ, Kallan MJ, et al. Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc 2002;50(5):823-8.

63. Stoppe G. Demenz. München: UTB Ernst Reinhardt; 2006.

64. Beekman AT, Deeg DJ, Braam AW, et al. Consequences of major and minor depression in later life: a study of disability, well-being and service utilization. Psychol Med 1997;27(6):1397-409.

65. Unutzer J, Patrick DL, Diehr P, et al. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr 2000;12(1):15-33.

66. Baldwin RC, Gallagley A, Gourlay M, et al. Prognosis of late life depression: a three-year cohort study of outcome and potential predictors. Int J Geriatr Psychiatry 2006;21(1):57-63.

67. Schulz R, Drayer RA, Rollman BL. Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry 2002;52(3):205-25.

68. Waern M, Runeson BS, Allebeck P, et al. Mental disorder in elderly suicides: a case-control study. Am J Psychiatry 2002;159(3):450-5.

69. Gleason OC, Pierce AM, Walker AE, et al. The two-way relationship between medical illness and late-life depression. Psychiatr Clin North Am 2013;36(4):533-44.

70. Meltzer H, Gill B, Petticrew M, et al. The prevalence of psychiatric morbidity among adults living in private households (OPCS surveys of psychiatric morbidity in Great Britain). London: Palgrave Macmillan; 1995.

71. Jacobi F, Hofler M, Siegert J, et al. Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res 2014;23(3):304-19.

72. Baumeister H, Kury S, Bengel J. Somato-psychische Komorbidität: Definition und Verständnis. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2011;54:9-14.

73. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29(2-3):85-96.

74. Jacobi F, Höfler M, Meister W, et al. Prävalenz, Erkennens- und Verschreibungsverhalten bei depressiven Syndromen. Eine bundesdeutsche Hausarztstudie. Nervenarzt 2002;73(7):651-8.

75. Wittchen HU. Critical issues in the evaluation of comorbidity of psychiatric disorders. Br J Psychiatry Suppl 1996;168(Suppl 30):9-16.

76. Frances A, Widiger T, Fyer MR. The influence of classification methods on comorbidity. In: Maser JD, Cloninger CR, editors. Comorbidity of mood and anxiety disorders. Washington: American Psyiatric Publishing; 1990. p. 41-59.

77. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996;168(Suppl 30):17-30.

78. Pincus HA, Zarin DA, Tanielian TL, et al. Psychiatric patients and treatments in 1997: findings from the American Psychiatric Practice Research Network. Arch Gen Psychiatry 1999;56(5):441-9.

79. Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999;60(Suppl 7):4-9.

80. Berger M, van Calker D. Affektive Störungen. In: Berger M, editor. Psychische Erkrankungen. Klinik und Therapie. München: Urban und Fischer; 2004.

81. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62(10):1097-106.

82. Kaufman J, Charney D. Comorbidity of mood and anxiety disorders. Depress Anxiety 2000;12(Suppl 1):69-76.

83. Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry 1998;34:24-8.

84. Bakish D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 1999;60(Suppl 6):20-4.

85. Goldney RD, Fisher LJ, Wilson DH, et al. Major depression and its associated morbidity and quality of life in a random, representative Australian community sample. Aust N Z J Psychiatry 2000;34(6):1022-9.

86. Grunhaus L, Pande AC, Brown MB, et al. Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. Am J Psychiatry 1994;151(4):541-6.

87. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Jama 1990;264(19):2511-8.

88. Raimo EB, Schuckit MA. Alcohol dependence and mood disorders. J Behav Addict 1998;23(6):933-46.

89. Halmi KA, Eckert E, Marchi P, et al. Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch Gen Psychiatry 1991;48(8):712-8.

90. Godart NT, Perdereau F, Rein Z, et al. Comorbidity studies of eating disorders and mood disorders. Critical review of the literature. J Affect Disord 2007;97(1-3):37-49.

91. Hirschfeld RM. Personality disorders and depression: comorbidity. Depress Anxiety 1999;10(4):142-6.

92. Skodol AE, Stout RL, McGlashan TH, et al. Co-occurrence of mood and personality disorders: a report from the Collaborative Longitudinal Personality Disorders Study (CLPS). Depress Anxiety 1999;10(4):175-82.

93. Keller MB, Gelenberg AJ, Hirschfeld RM, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59(11):598-607.

94. Pfohl B, Black DW, Noyes R, et al. Axis I and Axis II comorbidity findings: Implications for validity. In: Oldham JM, editor. Personality disorders: new perspectives on diagnostic validity. Washington: American Psychological Association; 1991. p. 147-61.

95. Tyrer P, Gunderson J, Lyons M, et al. Extent of comorbidity between mental state and personality disorders. J Pers Disord 1997;11(3):242-59.

96. Kapfhammer HP. Depressiv-ängstliche Störungen bei somatischen Krankheiten. Berlin: Springer; 2000.

97. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. Jama 1989;262(7):914-9.

98. Honda K, Goodwin RD. Cancer and mental disorders in a national community sample: Findings from the National Comorbidity Survey. Psychother Psychosom 2004;73(4):235-42.

99. Tiemeier H, van Dijck W, Hofman A, et al. Relationship between atherosclerosis and late-life depression: the Rotterdam Study. Arch Gen Psychiatry 2004;61(4):369-76.

100. Baumeister H, Höfler M, Jacobi F, et al. Psychische Störungen bei Patienten mit muskuloskelettalen und kardiovaskulären Erkrankungen im Vergleich zur Allgemeinbevölkerung. Z Klin Psychol Psychother 2004;33(1):33-41.

101. Patten SB. Long-term medical conditions and major depression in the Canadian population. Can J Psychiatry 1999;44(2):151-7.

102. Ormel J, Von Korff M, Oldehinkel AJ, et al. Onset of disability in depressed and non-depressed primary care patients. Psychol Med 1999;29(4):847-53.

103. Baumeister H, Korinthenberg K, Bengel J, et al. Psychische Störungen bei Asthma bronchiale - ein systematisches Review empirischer Studien. Psychother Psychosom Med 2005;55(5):247-55.

104. McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52(2):89-99.

105. Popkin MK, Callies AL, Lentz RD, et al. Prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus. Arch Gen Psychiatry 1988;45(1):64-8.

106. Miller AH, Pearce BD, Pariante CM. Immune system and central nervous system interactions. In: Sadock J, editor. Comprehensive textbook of psychiatry. London: Lippincott Williams and Wilkins; 2000. p. 113-33.

107. Härter M, Baumeister H, Reuter K, et al. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007;76(6):354-60.

108. Ormel J, Von Korff M, Burger H, et al. Mental disorders among persons with heart disease - results from World Mental Health surveys. Gen Hosp Psychiatry 2007;29(4):325-34.

109. Lin EH, Von Korff M, Alonso J, et al. Mental Disorders among Persons with Diabetes - Results from the World Mental Health Surveys. J Psychosom Res 2008;65(6):571-80.

110. Scott KM, Von Korff M, Ormel J, et al. Mental disorders among adults with asthma: results from the World Mental Health Survey. Gen Hosp Psychiatry 2007;29(2):123-33.

111. Baumeister H, Härter M. Mental disorders in patients with obesity in comparison with healthy probands. Int J Obes 2007;31:1155-64.

112. Baumeister H, Kriston L, Bengel J, et al. High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. J Clin Epidemiol 2010;63(5):558-65.

113. Mehnert A, Brahler E, Faller H, et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 2014;32(31):3540-6.

114. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004;66(6):802-13.

115. Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005;28(11):2668-72.

116. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29(2):147-55.

117. Hutter N, Knecht A, Baumeister H. Health care costs in persons with asthma and comor-bid mental disorders - a systematic review. Gen Hosp Psychiatry 2011;33:443-53.

118. Hutter N, Schnurr A, Baumeister H. Healthcare costs in persons with diabetes mellitus and comorbid mental disorders - a systematic review. Diabetologia 2010;53(12):2470–9.

119. Baumeister H, Knecht A, Hutter N. Direct and indirect costs in persons with chronic back pain and comorbid mental disorders - a systematic review. J Psychosom Res 2012;73(2):79-85.

120. Haschke A, Hutter N, Baumeister H. Indirect costs in patients with coronary artery disease and mental disorders: a systematic review and meta-analysis. Int J Occup Med Environ Health 2012;25(4):319-29.

121. Gonzalez JS, Safren SA, Cagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 2007;30(9):2222-7.

122. Ziegelstein RC, Fauerbach JA, Stevens SS, et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000;160(12):1818-23.

123. Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J Clin Epidemiol 2005;58(11):1090-100.

124. Baumeister H, Hutter N, Bengel J, et al. Quality of life in medically ill persons with comorbid mental disorders: a systematic review and meta-analysis. Psychother Psychosom 2011;80:275-86.

125. Patten SB, Beck CA, Kassam A, et al. Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry 2005;50(4):195-202.

126. Ferketich AK, Schwartzbaum JA, Frid DJ, et al. Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000;160(9):1261-8.

127. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94(12):3123-9.

128. Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? J Psychosom Res 2000;48(4-5):323-37.

129. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res 2000;48(4-5):379-91.

130. Callahan CM, Kroenke K, Counsell SR, et al. Treatment of depression improves physical functioning in older adults. J Am Geriatr Soc 2005;53(3):367-73.

131. Mazza M, Lotrionte M, Biondi-Zoccai G, et al. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol 2010;24(12):1785-92.

132. Kales HC, Maixner DF, Mellow AM. Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry 2005;13(2):88-98.

133. Tiemeier H. Biological risk factors for late life depression. Eur J Epidemiol 2003;18(8):745-50.

134. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol Scand 2006;113(1):1-8.

135. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997;54(10):915-22.

136. Stoppe G. Depressionen bei Alzheimer Demenz. In: Calabrese P, Förstl H, editors. Psychopathologie und Neuropsychologie der Demenz. Lengerich: Pabst; 2000. p. 68-86.

137. Stoppe G. Alte. In: Stoppe G, Bramesfeld A, Schwartz FW, editors. Volkskrankheit Depression. Berlin: Springer; 2006.

138. Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63(5):530-8.

139. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367(9524):1747-57.

140. Murray CJ, Lopez AD. Global and regional descriptive epidemiology of disability: Incidence, prevalence, health expectancies and years lived with disability. In: Murray CJ, Lopez AD, editors. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard: Harvard University Press; 1997. p. 201-46.

141. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184(MAY):386-92.

142. World Health Organization (WHO). The global burden of disease. 2004 Update. Geneva: 2004 [cited: 2016-09-14]. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.

143. Arolt V, Rothermundt M. Depressive Störungen bei körperlich Kranken. Nervenarzt 2003;74(11):1033-52.

144. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004;61(10):1042-9.

145. Koike AK, Unützer J, Wells KB. Improving the care for depression in patients with comorbid medical illness. Am J Psychiatry 2002;159(10):1738-45.

146. Schneider F, Falkai P, Maier W. Psychiatrie 2020 plus. Berlin, Heidelberg: Springer; 2012.

147. Statistisches B. Gesundheit: Todesursachen in Deutschland 2013. 2014 [cited: 2016-09-14]. http://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Todesursachen/Todesursachen2120400137004.pdf?__blob=publicationFile.

148. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170(3):205-28.

149. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000;157(12):1925-32.

150. Härter M, Sitta P, Keller F, et al. Stationäre psychiatrisch-psychotherapeutische Depressionsbehandlung - Prozess- und Ergebnisqualität anhand eines Modellprojektes in Baden-Württemberg. Nervenarzt 2004;75(11):1083-91.

151. Althaus D. Das „Nürnberger Bündnis gegen Depression". Zwischenauswertung eines depressions- und suizidpräventiven Programms nach 12 Monaten Laufzeit. München: Ludwig-Maximilians-Universität; 2004.

152. Hegerl U. Depression und Suizidalität. Verhaltenstherapie 2005;15(1):6-11.

153. World Health Organization (WHO). The global burden of disease: 2004 update. Geneva: 2008 [cited: 2016-09-14]. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.

154. Statistisches B. Gesundheit: Todesursachen in Deutschland 2012. 2013 [cited: 2016-09-14]. http://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Todesursachen/Todesursachen2120400127004.pdf?__blob=publicationFile.

155. Deutsche Gesellschaft für Psychiatrie PuND. S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. AWMF-Register Nr. 038-020. Heidelberg: Springer; 2012.

156. Ramchandani P, A, S. The impact of parental psychiatric disorder on children. Bmj 2003;327(7409):242-3.

157. Goodman SH, Gotlib IH. Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Psychol Rev 1999;106(3):458-90.

158. Melchior H, Schulz H, Härter M. Faktencheck Gesundheit. Regionale Unterschiede in der Diagnostik und Behandlung von Depressionen. 2014 [cited: 2016-09-14]. http://depression.faktencheck-gesundheit.de/fachinformation/fachinformation-startseite.

159. Berndt ER, Finkelstein SN, Greenberg PE, et al. Workplace performance effects from chronic depression and its treatment. J Health Econ 1998;17(5):511-35.

160. Ormel J, Von Korff M, Ustun TB, et al. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. Jama 1994;272(22):1741-8.

161. IGES IG. Analyse der Arbeitsunfähigkeitsdaten. DAK-Gesundheitsreport 2014. Hamburg: 2014 [cited: 2016-09-14]. http://www.dak.de/dak/download/Gesundheitsreport_2014_Die_Rushhour_des_Lebens-1374440.pdf.

162. Statistisches Bundesamt. Krankheitskosten. 2013 [cited: 2016-09-14]. http://www.gbe-bund.de.

163. Zivin K, Wharton T, Rostant O. The economic, public health, and caregiver burden of late-life depression. Psychiatr Clin North Am 2013;36(4):631-49.

164. Busch MA, Neuner B, Aichberger MC. Depressive Symptomatik und Inanspruchnahme von Gesundheits- und Pflegeleistungen bei Personen im Alter ab 50 Jahren in Deutschland. Ergebnisse einer bevölkerungsbasierten Querschnittstudie. Psychiatr Prax 2013;40:214-9.

165. Luppa M, Sikorski C, Motzek T, et al. Health service utilization and costs of depressive symptoms in late life - a systematic review. Curr Pharm Des 2012;18(36):5936-57.

166. Riedel-Heller SG, Luppa M. Depression im Alter - was trägt die aktuelle epidemiologische Forschung bei? Psychiatr Prax 2013;40(04):173-5.

167. Friemel S, Bernert S, Angermeyer MC, et al. Die direkten Kosten von depressiven Erkrankungen in Deutschland: Ergebnisse aus dem European Study of the Epidemiology of Mental Disorders (ESEMeD) Projekt. Psychiatr Prax 2005;32(3):113-21.

168. Stamm K, Reinhard I, Salize HJ. Kosten und Kostenverläufe von Versicherten mit Depressionsdiagnose und ohne psychische Störung im Vergleich - eine Sekundäranalyse von Routinedaten einer Betriebskrankenkasse. Neuropsychiatr 2010;24(2):99-107.

169. Stamm K, Salize HJ, Härter M, et al. Ressourcenverbrauch stationärer Episoden bei depressiven Störungen. Eine Analyse aus Sicht der Krankenkassen. Nervenarzt 2007;78(6):665-71.

170. Kleine-Budde K, Müller R, Kawohl W, et al. The cost of depression - a cost analysis from a large database. J Affect Disord 2013;147(1–3):137-43.

171. Statistisches Bundesamt. Verlorene Erwerbstätigkeitsjahre. 2013 [cited: 2016-09-14]. http://www.gbe-bund.de.

172. Statistisches Bundesamt. Rentenzugänge wegen verminderter Erwerbsfähigkeit in der Gesetzlichen Rentenversicherung. 2013 [cited: 2016-09-14]. http://www.gbe-bund.de.

173. Sartorius N. The economic and social burden of depression. J Clin Psychiatry 2001;62(Suppl 15):8-11.

174. Priest RG, Vize C, Roberts A, et al. Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. Bmj 1996;313(7061):858-9.

175. Glozier N. Workplace effects of the stigmatization of depression. J Occup Environ Med 1998;40(9):793-800.

176. Aldenhoff J. Überlegungen zur Psychobiologie der Depression. Nervenarzt 1997;68(5):379-89.

177. Hautzinger M. Kognitive Verhaltenstherapie bei Depressionen. 6 ed. Weinheim: Beltz; 2003.

178. Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic-depressive disorders. Br J Psychiatry 1977;130(4):330-51.

179. Matussek N, Holsboer F. Biologischer Hintergrund. In: Kisker H, Lauter H, Meyer JE, et al, editors. Psychiatrie der Gegenwart. Bd. 5: Affektive Psychosen. Berlin: Springer; 1987. p. 165-80.

180. Nurnberger JI, Gershon ES. Genetics. In: Paykel ES, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone; 1992. p. 131-48.

181. Propping P. Psychiatrische Genetik. Befunde und Konzepte. Berlin: Springer; 1989.

182. Tsuang MT, Faraone SV. The genetics of mood disorders. Baltimore: John Hopkins University Press; 1990.

183. Zerbin-Rüding E. Psychiatrische Genetik. In: Kisker KP, Meyer JE, Müller C, et al, editors. Grundlagen und Methoden der Psychiatrie. Teil 2. Berlin: Springer; 1980. p. 545-618.

184. Hammen C. Depression runs in families: the social context of risk and resilience in children of depressed mothers. New York: Springer; 1991.

185. Hautzinger M. Affektive Störungen. In: Ehlers A, Hahlweg K, editors. Psychische Störungen und ihre Behandlung. Göttingen: Hogrefe; 1997. p. 156-239.

186. Seligman MEP. Helplessness. San Francisco: Freeman; 1975.

187. Deutsche Gesellschaft für Psychiatrie PuND. Positionspapier der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) zum Thema Burnout. Berlin: 2012 [cited: 2016-09-14]. http://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/stellungnahmen/2012/stn-2012-03-07-burnout.pdf.

188. Weymann N, Unger HP, Dirmaier J, et al. Burnout. 2014 [cited: 2016-09-14]. http://www.psychenet.de/psychische-gesundheit/informationen/burnout.html.

189. Bowlby J. Separation: anxiety and anger. New York: Basic Books; 1973.

190. Harlow HF, Harlow MK. The affectional systems. In: Schrier A, Harlow H, Stollnitz F, editors. Behavior of nonhuman primates. 2 ed. New York: Academ Press; 1965.

191. Bowlby J. Attachment and loss. 1: Attachment ed. New York: Basic Books; 1969.

192. Agid O, Shapira B, Zislin J, et al. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol Psychiatry 1999;4(2):163-72.

193. Barnes GE, Prosen H. Parental death and depression. J Abnorm Psychol 1985;94(1):64-9.

194. Crook T, Eliot J. Parental death during childhood and adult depression: a critical review of the literature. Psychol Bull 1980;87(2):252-9.

195. Lara ME, Klein DN. Psychosocial processes underlying the maintenance and persistence of depression: implications for understanding chronic depression. Clin Psychol Rev 1999;19(5):553-70.

196. Siegrist J. Chronic psychosocial stress at work and risk of depression: evidence from prospective studies. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 5):115-9.

197. Kristeva J. Schwarze Sonne. Depression und Melancholie. Frankfurt: Brandes und Apsel; 2007.

198. Green A. Die tote Mutter. Psyche 1993;47(3):205-40.

199. Reck C, Backenstrass M, Mundt C. Depression und interaktive Affektregulation. In: Böker H, Hell D, editors. Therapie der affektiven Störungen. Stuttgart: Schattauer; 2002. p. 45-54.

200. Tronick EZ, Weinberg MK. Depressed mothers and infants: Failure to form dyadid states of consciousness. In: Murray L, Cooper PJ, editors. Postpartum depression and child development. New York: Guilford Press; 1997. p. 54–81.

201. Lewinsohn PM. A behavioral approach to depression. In: Friedman RJ, Katz MM, editors. Innovative treatment methodes of psychopathology. New York: Wiley; 1974. p. 88-102.

202. Lewinsohn PM, Youngren MA, Grosscup SJ. Reinforcement and depression. In: Depue RA, editor. The psychobiology of the depressive disorders. New York: Academic Press; 1979.

203. Paykel ES, Cooper Z. Life events and social stress. In: Paykel ES, editor. Handbook of affectives disorders. Edinburgh: Churchill Livingstone; 1992.

204. Brakemeier EL, Normann C, Berger M. Äthiopathologische Modelle der Depression: Neurobiologische und psychosoziale Faktoren. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2008;51(4):379-91.

205. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama 2003;289(23):3095-105.

206. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-5). Washington, DC: American Psychiatric Association; 2013.

207. Keller MB, Klerman GL, Lavori PW, et al. Long-term outcome of episodes of major depression. Clinical and public health significance. Jama 1984;252(6):788-92.

208. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49(10):809-16.

209. Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999;60(Suppl 17):41-5.

210. Spijker J, de Graaf R, Bijl RV, et al. Duration of major depressive episodes in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002;181(3):208-13.

211. Angst J. Course of mood disorders: a challenge to psychopharmacology. Clin Neuropharmacol 1992;15:444A-5A.

212. Boland RJ, Keller MB. Course and outcome of depression. In: Gotlib IH, Hammen CL, editors. Handbook of depression. New York: Guilford Press; 2002. p. 43-60.

213. Thornicroft G, Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment of Depressive Disorders. Psychol Med 1993;23(4):1023-32.

214. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(Suppl 5):28-34.

215. Olfson M, Shea S, Feder A, et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Archives of family medicine 2000;2000/10/14(9):876-83.

216. Angst J. The course of affective disorders. Psychopathology 1986;19(Suppl 2):47-52.

217. Meyer TD, Hautzinger M. Manisch-depressive Störungen: Kognitiv-verhaltenstherapeutisches Behandlungsmanual. Weinheim: Beltz; 2004.

218. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988;104(1):84-96.

219. Hautzinger M, Jong-Meyer R. Zwei Multizenter-Studien zur Wirksamkeit von Verhaltenstherapie, Pharmakotherapie und deren Kombination bei depressiven Patienten: Einführung, Rahmenbedingungen und Aufgabenstellung. Z Klin Psychol Psychother 1996;25(2):83-92.

220. Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch Gen Psychiatry 1992;49(10):774-81.

221. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. In: American Psychiatric Association, editor. Practice guidelines for the treatment of people with psychiatric disorders. Washington: American Psychiatric Association (APA); 2000. p. 413-96.

222. Canadian Psychiatric Association (CPA). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46(Suppl 1):5S-90S.

223. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60(Suppl 22):29-34.

224. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50(2-3):97-108.

225. Keller MB. Dysthymia in clinical practice: course, outcome and impact on the community. Acta Psychiatr Scand 1994;383(Suppl):24-34.

226. Gaebel W, Falkai P. Praxisleitlinien in der Psychiatrie: Behandlungsleitline Affektive Erkrankungen. Darmstadt: Steinkopff; 2000.

227. Keitner GI, Ryan CE, Miller IW, et al. Recovery and major depression: factors associated with twelve-month outcome. Am J Psychiatry 1992;149(1):93-9.

228. Giles DE, Jarrett RB, Biggs MM, et al. Clinical predictors of recurrence in depression. Am J Psychiatry 1989;146(6):764-7.

229. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156(7):1000-6.

230. Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry 2005;162(9):1588-601.

231. World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.

232. Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med 2008;40(2):149-59.

233. Nakao M, Yano E. Prediction of major depression in Japanese adults: somatic manifestation of depression in annual health examinations. J Affect Disord 2006;90(1):29-35.

234. Posternak MA, Solomon DA, Leon AC, et al. The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Ment Dis 2006;194(5):324-9.

235. Hegeman JM, Kok RM, van der Mast RC, et al. Phenomenology of depression in older compared with younger adults: meta-analysis. Br J Psychiatry 2012;200(4):275-81.

236. Deutsche Gesellschaft für Bipolare Störungen (DGBS), Deutsche Gesellschaft für Psychiatrie PuND. S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.0. DGBS e.V. und DGPPN e.V.; 2012.

237. American Psychiatric Association (APA). Diagnostisches und Statistisches Manual Psychischer Störungen - DSM-5: Deutsche Ausgabe. Göttingen: Hogrefe; 2014.

238. Steglitz RD, Freyberger HJ. DSM-5 und ICD-10: Was kommt auf uns zu? Psychother Psychosom Med 2013;63:207.

239. Jacobi F, Maier W, Heinz A. Hilfestellung zur Indikation. Dtsch Arztebl 2013;110(49):2364-8.

240. Härter M, Bermejo I, Niebling W. Praxismanual Depression – Diagnostik und Therapie erfolgreich umsetzen. Köln: Deutscher Ärzteverlag; 2007.

241. National Collaborating Centre for Mental Health. Depression: Management of depression in primary and secondary care. Clinical Guideline 23. London: 2004 [cited: 2016-09-14]. http://www.scamfyc.org/documentos/depresion%20NICE.pdf.

242. Whooley MA, Avins AL, Miranda J, et al. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997;12(7):439-45.

243. Rudolf S, Bermejo I, Schweiger U, et al. Diagnostik depressiver Störungen in Praxis und klinischem Alltag. Dtsch Arztebl 2006;103(25):A-1754.

244. World Health Organization (WHO). Wellbeing measures in primary health care: the DepCare project. Copenhagen: World Health Organization; 1998.

245. Löwe B, Spitzer RL, Zipfel S, et al. PHQ-D - Gesundheitsfragebogen für Patienten. Karlsruhe: Pfizer; 2001.

246. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. Jama 1999;282(18):1737-44.

247. Hautzinger M, Bailer M. Die Allgemeine Depressionsskala. Weinheim: Beltz; 2005.

248. Gensichen J, Huchzermeier C, Aldenhoff JB, et al. Signalsituationen für den Beginn einer strukturierten Depressionsdiagnostik in der Allgemeinarztpraxis - Eine praxis-kritische Einschätzung internationaler Leitlinien. Z Arztl Fortbild Qualitatssich 2005;99(1):57-63.

249. Gilbody S, House AO, Sheldon TA. Screening and case finding instruments for depression. Cochrane Database Syst Rev 2005;CD002792.

250. Deutsche Gesellschaft für Psychiatrie PuND. S3 Praxisleitlinien in Psychiatrie und Psychotherapie - Band 1: Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff; 2006.

251. Müller-Spahn F. Depressionen im höheren Lebensalter. In: Gaebel W, Müller-Spahn F, editors. Diagnostik und Therapie psychischer Störungen. Stuttgart: Kohlhammer; 2002. p. 448-63.

252. Pies R. Clinical manual of psychiatric diagnosis and treatment. Washington: American Psychiatric Press; 1994.

253. Wittchen HU, Semler G. Composite International Diagnostic Interview (CIDI, Version 1.0). Weinheim: Beltz; 1990.

254. Wittchen HU, Pfister H. DIA-X Interviews: Manual für Screening, Verfahren und Interview, Interviewheft Längsschnittuntersuchung (DIA-X lifetime); Ergänzungsheft (DIA-X), Interviewheft Querschnittuntersuchung (DIA-X 12 Monate); PC-Programm zur Durchführung des Interviews (Längs- und Querschnittsuntersuchung); Auswertungsprogramm. Frankfurt: Swets und Zeitlinger; 1997.

255. Kasper S, Möller HJ. Depression: Diagnose und Pharmakotherapie. Stuttgart: Thieme; 1997.

256. Möller HJ. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand 2003;108(Suppl 418):73-80.

257. Wolfersdorf M, Mäulen B. Suizidprävention bei psychisch Kranken. In: Wedler H, Wolfersdorf M, Welz R, editors. Therapie bei Suizidgefährdung. Regensburg: Röderer; 1992. p. 175-97.

258. Kocalevent RD, Hegerl U. Depression und Suizidalität. Public Health Forum 2010;18(1):13-4.

259. Robert Koch-Institut (RKI). Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch-Institut; 2006.

260. Hiller W, Zaudig M, Mombour W. IDCL - internationale Diagnosen Checklisten für ICD-10 und DSM-IV: Manual. Bern: Huber; 1995.

261. Bartling G, Echelmeyer L, Engberding M. Problemanalyse im therapeutischen Prozess: Leitfaden für die Praxis. Stuttgart: Kohlmeyer; 1998.

262. Schulte D. Therapieplanung. Göttingen: Hogrefe; 1996.

263. Kennedy SH. Treating depression effectively - applying clinical guidelines. Cambridge: Dunitz; 2004.

264. Ahrens B, Grunze H, Hiemke C, et al. Behandlung affektiver Erkrankungen. In: Möller HJ, editor. Therapie psychiatrischer Erkrankungen. 2 ed. Stuttgart: Thieme; 2000. p. 300-482.

265. Hautzinger M, Meyer TD. Diagnostik affektiver Störungen. Göttingen: Hogrefe; 2002.

266. Beck AT, Steer RA, Brown GK. Beck Depression Inventory. Manual. 2 ed. San Antonio: Psychological Corporation; 1996.

267. Hautzinger M, Keller F, Kühner C. BDI-II-Depressionsinventar. 2 ed. Frankfurt: Harcourt Test Services; 2006.

268. Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale - Deutsche Version (HADS-D). Manual. Berlin: Huber; 1993.

269. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin Gerontol 1986;5(1-2):165-73.

270. Fischer GC. Ambulantes geriatrischgerontologisches Screening in der Primärversorgung. Hannover: Norddeutscher Forschungsverbund Public Health; 1988.

271. Kühner C. Fragebogen zur Depressionsdiagnostik nach DSM-IV (FDD-DSM-IV). Göttingen: Hogrefe; 1997.

272. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.

273. Bech P, Rafaelsen OJ. The melancholia scale: development, consistency, validity and utility. In: Satorius N, Ban TA, editors. Assessment of depression. Berlin: Springer; 1986. p. 259-69.

274. Stieglitz RD, Wolfersdorf M, Metzger R, et al. Stationäre Behandlung depressiver Patienten. Konzeptuelle Überlegungen und Ergebnisse eines Pilotprojekts zur Qualitätssicherung in Baden-Württemberg. Nervenarzt 1998;69(1):59-65.

275. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134(4):382-9.

276. Neumann N, Schulte R. Montgomery-Asperg-Depressions-Rating-Skala zur psychometrischen Beurteilung depressiver Syndrome. Deutsche Fassung. Erlangen: Perimed-Fachbuch; 1989.

277. Watzke B, Heddaeus D, Steinmann M, et al. Gestuftes Vorgehen (Stepped-Care) bei der Behandlung von Patienten mit Depressionen. Bericht über das Gesundheitsnetz Depression im psychenet - Hamburger Netz psychische Gesundheit. Verhaltenstherapie und Psychosoziale Praxis 2014;46(2):455-8.

278. Härter M, Heddaeus D, Steinmann M, et al. Collaborative und Stepped Care bei depressiven Erkrankungen: Entwicklung eines Modellprojektes im Hamburger Netz psychische Gesundheit (psychenet.de). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2015;58(4):420-9.

279. Gensichen J, Petersen JJ, Von Korff M, et al. Cost-effectiveness of depression case management in small practices. Br J Psychiatry 2013;202(6):441-6.

280. Ferrier IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999;60(Suppl 6):10-4.

281. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. Jama 2003;289(23):3152-60.

282. Lecrubier Y. How do you define remission? Acta Psychiatr Scand 2002;106(Suppl 415):7-11.

283. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(Suppl 22):7-11.

284. Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand Suppl 2002;106(Suppl 415):12-7.

285. Rudolph RL. Goal of antidepressant therapy: response or remission and recovery? J Clin Psychiatry 1999;60(Suppl 6):3-4.

286. Thase ME. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 1999;60(Suppl 6):15-9.

287. Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 2003;64(Suppl 2):3-7.

288. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003;64(Suppl 13):18-25.

289. Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 2006;163(1):148-50.

290. The Management of Major Depressive Disorder Working Group. VHA/DOD Clinical Practice Guideline for the Management of Major Depressive Disorder in Adults. Version 2.0. 2000 [cited: 2016-09-14]. http://www.healthquality.va.gov/mdd/mdd_cpg_v21.pdf.

291. Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999;60(3):142-56.

292. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361(9358):653-61.

293. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998;5(6):293-306.

294. Deutsche Gesellschaft für Psychotherapeutische Medizin (DGPM), Deutsche Gesellschaft für Psychoanalyse PPuTD, Deutsches Kollegium Psychosomatische Medizin (DKPM), et al. Psychotherapie der Depression. 2002 [cited: 2016-09-14]. http://www.aerzteblatt.de/download/files/2004/07/x0001045.pdf.

295. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003;64(Suppl 15):13-7.

296. Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J Psychopharmacol 2006;20(3 Suppl):19-28.

297. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47(12):1093-9.

298. Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004;161(10):1872-6.

299. Jacob G, Bengel J. Das Konstrukt Patientenzufriedenheit: Eine kritische Bestandsaufnahme. Z Klin Psychol Psychiatr Psychother 2000;48(3):280-301.

300. O'Connor LE, Berry JW, Weiss J, et al. Guilt, fear, submission, and empathy in depression. J Affect Disord 2002;71(1-3):19-27.

301. Wolfersdorf M. Krankheit Depression. Erkennen, verstehen und behandeln. Bonn: Psychiatrie-Verlag; 2002.

302. Liebherz S, Tlach L, Sänger S, et al. Entscheidungshilfe Depressionen. 2014 [cited: 2016-09-14]. http://entscheidungshilfen.psychenet.de/depression/was-ist-eine-depression.html.

303. Liebherz S, Dirmaier J, Härter M, et al. Faktencheck Depression. Nutzen und Risiken der Therapien. 2014 [cited: 2016-09-14]. http://faktencheck-gesundheit.de/fileadmin/files/Faktencheck/Dokumente/Faktenboxen-PDFs/Faktencheck-Depression_Faktenbox_Psychotherapie.pdf.

304. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Gesundheitsinformation. Depression. 2013 [cited: 2016-09-14]. http://www.gesundheitsinformation.de/depression.2125.de.html.

305. Tlach L, Wusten C, Daubmann A, et al. Information and decision-making needs among people with mental disorders: a systematic review of the literature. Health Expect 2014;21(10):12251.

306. Trenckmann U, Bandelow B. Empfehlungen zur Patienteninformation Psychiatrie und Psychotherapie. Darmstadt: Steinkopff; 2002.

307. Loh A, Kremer N, Giersdorf N, et al. Informations- und Partizipationsinteressen depressiver Patienten bei der medizinischen Entscheidungsfindung in der hausärztlichen Versorgung. Z Arztl Fortbild Qualitatssich 2004;98(2):101-7.

308. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011;CD001431.

309. Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014;CD001431.

310. Luderer HJ. Rechtsfragen. In: Bäuml J, Pitschel-Walz G, editors. Psychoedukation bei schizophrenen Erkrankungen. München: Schattauer; 2003. p. 269-86.

311. Elwyn G, Edwards A, Britten N. What information do patients need about medicines? "Doing prescribing": how doctors can be more effective. Bmj 2003;327(7419):864-7.

312. Loh A, Meier K, Simon D, et al. Entwicklung und Evaluation eines Fortbildungsprogramms zur Partizipativen Entscheidungsfindung für die hausärztliche Versorgung depressiver Patienten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2004;47(10):977-84.

313. Elwyn G, Edwards A, Mowle S, et al. Measuring the involvement of patients in shared decision-making: a systematic review of instruments. Patient Educ Couns 2001;43(1):5-22.

314. Härter M, Loh A, Spies C. Gemeinsam entscheiden-erfolgreich behandeln. Neue Wege für Ärzte und Patienten im Gesundheitswesen. Köln: Deutscher Ärzte-Verlag; 2005.

315. Loh A, Simon D, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen - Effekte der Partizipativen Entscheidungsfindung aus systematischen Reviews. Dtsch Arztebl 2007;104(21):A-1483.

316. Loh A, Leonhart R, Wills CE, et al. The impact of patient participation on adherence and clinical outcome in primary care of depression. Patient Educ Couns 2007;65(1):69-78.

317. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making 2015;35(1):114-31.

318. Goldman CR, Quinn FL. Effects of a patient education program in the treatment of schizophrenia. Hosp Community Psychiatry 1988;39(3):282-6.

319. Bäuml J, Pitschel-Walz G. Psychoedukation bei schizophrenen Erkrankungen. München: Schattauer; 2003.

320. Kronmüller KT, Kratz B, Karr M, et al. Inanspruchnahme eines psychoedukativen Gruppenangebotes für Angehörige von Patienten mit affektiven Störungen. Nervenarzt 2006;77(3):318-26.

321. Kronmüller KT, Karr M, Backenstrass M. Familienorientierte Behandlung der Depression - das Heidelberger Stufenkonzept. In: Deutsche PA, editor. Psychologie am Puls der Zeit. Bonn: Deutscher Psychologen Verlag; 2001. p. 284-7.

322. Mahnkopf A, Rahn E. Angehörigenarbeit in der Depressionsbehandlung. In: Wolfersdorf M, editor. Depressionsstationen - stationäre Depressionsbehandlung. Berlin: Springer; 1997. p. 35-46.

323. Schaub A. Angehörigenarbeit und psychoedukative Patientengruppen in der Therapie affektiver Störungen. In: Möller HJ, editor. Therapie psychischer Erkrankungen. Stuttgart: Thieme; 2000. p. 462-73.

324. Schramm E. Interpersonelle Psychotherapie. Stuttgart: Schattauer; 2003.

325. Dietrich G, Wagner P, Bräunig P. Psychoedukation in der Behandlung bipolarer affektiver Erkrankungen. Psychoneuro 2003;29(09):403-8.

326. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003;60(2):145-52.

327. Rouget BW, Aubry JM. Efficacy of psychoeducational approaches on bipolar disorders: a review of the literature. J Affect Disord 2007;98(1-2):11-27.

328. Bernhard B, Schaub A, Kummler P, et al. Impact of cognitive-psychoeducational interventions in bipolar patients and their relatives. Eur Psychiatry 2006;21(2):81-6.

329. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60(4):402-7.

330. Colom F, Lam D. Psychoeducation: improving outcomes in bipolar disorder. Eur Psychiatry 2005;20(5-6):359-64.

331. Anderson CM, Griffin S, Rossi A, et al. A comparative study of the impact of education vs. process groups for families of patients with affective disorders. Fam Process 1986;25(2):185-205.

332. Glick ID, Burti L, Okonogi K, et al. Effectiveness in psychiatric care. III: Psychoeducation and outcome for patients with major affective disorder and their families. Br J Psychiatry 1994;164(1):104-6.

333. Jacob M, Frank E, Kupfer DJ, et al. A psychoeducational workshop for depressed patients, family, and friends: description and evaluation. Hosp Community Psychiatry 1987;38(9):968-72.

334. Dowrick C, Dunn G, Ayuso-Mateos JL, et al. Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. Br J Psychiatry 2000;321(7274):1450-4.

335. Swan J, Sorrell E, MacVicar B, et al. "Coping with depression": an open study of the efficacy of a group psychoeducational intervention in chronic, treatment-refractory depression. J Affect Disord 2004;82(1):125-9.

336. Vieweg T, Trabert W. Psychoedukation in der Depressionsbehandlung. Ein psychoedukatives Gruppenprogramm im Rahmen stationärer Psychotherapie. Verhaltenstherapie und Verhaltensmedizin 2002;23(4):479-97.

337. Harter C, Kick J, Rave-Schwank M. Psychoedukative Gruppen für depressive Patienten und ihre Angehörigen. Psychiatr Prax 2002;29(3):160-3.

338. Heru AM, Ryan CE, Madrid H. Psychoeducation for caregivers of patients with chronic mood disorders. Bull Menninger Clin 2005;69(4):331-40.

339. Sanford M, Boyle M, McCleary L, et al. A pilot study of adjunctive family psychoeducation in adolescent major depression: feasibility and treatment effect. J Am Acad Child Adolesc Psychiatry 2006;45(4):386-495.

340. Keller F, Schuler B. Angehörigengruppen in der stationären Depressionsbehandlung - Ergebnisse und Erfahrungen mit einem personenzentrierten Ansatz. Psychiatr Prax 2002;29(3):130-5.

341. Srinivasan J, Cohen NL, Parikh SV. Patient attitudes regarding causes of depression: implications for psychoeducation. Can J Psychiatry 2003;48(7):493-5.

342. Tursi MF, Baes C, Camacho FR, et al. Effectiveness of psychoeducation for depression: a systematic review. Aust N Z J Psychiatry 2013;47(11):1019-31.

343. Bermejo I, Lohmann A, Berger M, et al. Barrieren und Unterstützungsbedarf in der hausärztlichen Versorgung depressiver Patienten. Z Arztl Fortbild Qualitatssich 2002;96(9):605-13.

344. Höfler M, Wittchen HU. Why do primary care doctors diagnose depression when diagnostic criteria are not met? Int J Methods Psychiatr Res 2000;9(3):110-20.

345. Radisch J, Büchtemann D, Kästner D, et al. Eine literatur- und expertengestützte Analyse der Versorgungspraxis von depressiv erkrankten Menschen in Deutschland. Psychiatrische Praxis 2013;40:252-8.

346. Schneider F, Kratz S, Bermejo I, et al. Insufficient depression treatment in outpatient settings. Ger Med Sci 2004;26(2).

347. Matzat J. Selbsthilfegruppen für psychisch Kranke - Ergebnisse einer Umfrage bei Selbsthilfe-Kontaktstellen. In: Deutsche AS, editor. Selbsthilfegruppenjahrbuch 2004. Gießen: Focus Verlag; 2004. p. 153-60.

348. Wittchen HU, Winter S, Höfler M, et al. Häufigkeit und Erkennensrate von Depressionen in der hausärztlichen Praxis. Fortschr Med 2000;118(Sonderheft 1):22-30.

349. Sekera E, Archinard H, Stalder H. Depression. Strategien für die ambulante Medizin. Prim Care 2004;4:314-8.

350. Gerste B, Roick C. Prävalenz und Inzidenz sowie Versorgung depressiver Erkrankungen in Deutschland. Stuttgart: Schattauer; 2014.

351. Gilbody S, Whitty P, Grimshaw J, et al. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. Jama 2003;289(23):3145-51.

352. Bundesärztekammer (BÄK). Curriculum Psychosomatische Grundversorgung - Basisdiagnostik und Basisversorgung bei Patienten mit psychischen und psychosomatischen Störungen einschließlich Aspekte der Qualitätssicherung. Köln: 2001 [cited: 2016-09-14]. http://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/Currpsych.pdf.

353. Knowles SE, Toms G, Sanders C, et al. Qualitative meta-synthesis of user experience of computerised therapy for depression and anxiety. PLoS One 2014;9(1):e84323.

354. Huibers MJ, Beurskens AJ, Bleijenberg G, et al. Psychosocial interventions by general practitioners. Cochrane Database Syst Rev 2007;CD003494.

355. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. Bmj 1995;310(6977):441-5.

356. Linde K, Sigterman K, Kriston L, et al. Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis. Ann Fam Med 2015;13(1):56-68.

357. Gerlach I, Brenk-Franz K, Gensichen J. Qualifizierung von MFA für delegierbare Tätigkeiten in der häuslichen Umgebung von allgemeinärztlichen Patienten. Z Allg Med 2011;87(6):280-6.

358. Sikorski C, Luppa M, Konig HH, et al. Does GP training in depression care affect patient outcome? - A systematic review and meta-analysis. BMC Health Serv Res 2012;12:10.

359. Wernher I, Bjerregaard F, Tinsel I, et al. Collaborative treatment of late-life depression in primary care (GermanIMPACT): study protocol of a cluster-randomized controlled trial. Trials 2014;15(351):1745-6215.

360. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005;3(5):449-56.

361. Schneider F, Härter M, Brand S, et al. Adherence to guidelines for treatment of depression in in-patients. Br J Psychiatry 2005;187:462-9.

362. Bower P, Gask L. The changing nature of consultation-liaison in primary care: bridging the gap between research and practice. Gen Hosp Psychiatry 2002;24(2):63-70.

363. Richards DA, Lovell K, Gilbody S, et al. Collaborative care for depression in UK primary care: a randomized controlled trial. Psychol Med 2008;38(2):279-87.

364. Katon WJ, Seelig M. Population-based care of depression: team care approaches to improving outcomes. J Occup Environ Med 2008;50(4):459-67.

365. Fritze J, Schmauß M. Psychiatrische Versorgung in Deutschland. Personalprobleme? Nervenarzt 2001;72(10):824-7.

366. Angermeyer MC, Matschinger H. Have there been any changes in the public's attitudes towards psychiatric treatment? Results from representative population surveys in Germany in the years 1990 and 2001. Acta Psychiatr Scand 2005;111(1):68-73.

367. Gemeinsamer Bundesausschuss (GBA). Soziotherapie-Richtlinie - ST-RL. 2015 [cited: 2016-09-14]. http://www.g-ba.de/informationen/richtlinien/24/#tab/beschluesse/details/2158/listContext/beschluesse.

368. Watzke B, Büscher C, Koch U, et al. Leitlinienentwicklung bei der Behandlung von Patienten mit psychischen Störungen. In: Pawils S, Koch U, editors. Psychosoziale Versorgung in der Medizin. Stuttgart: Schattauer; 2006. p. 85-99.

369. Statistisches B. Gesundheit: Grunddaten der Krankenhäuser 2013. 2014 [cited: 2016-09-14]. http://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/GrunddatenKrankenhaeuser2120611137004.pdf?__blob=publicationFile.

370. Wolfersdorf M. Depressionsstationen Stand 2002 - eine Standortbestimmung. Krankenhauspsych 2003;14(02):44-8.

371. Wolfersdorf M, Lehle B. Depressionsstationen - Struktur- und Prozessqualität Stand 1998. Psychiatr Prax 2003;30(Suppl 2):140-2.

372. Wolfersdorf M, Muller B. Zur Situation der stationären Depressionsbehandlung in Deutschland. Psychiatr Prax 2007;34(Suppl 3):S277-S280.

373. Schramm E, van Calker D, Dykierek P, et al. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: Acute and long-term results. Am J Psychiatry 2007;164(5):768-77.

374. Liebherz S, Rabung S. Wirksamkeit psychotherapeutischer Krankenhausbehandlung im deutschsprachigen Raum: eine Meta-Analyse. Psychother Psychosom Med 2013;63(9-10):355-64.

375. Tritt K, von Heymann F, Loew TH, et al. Patienten in stationärer psychosomatischer Krankenhausbehandlung: Patientencharakteristika und Behandlungsergebnisse anhand der Psy-Bado-PTM. Psychother Psychosom Med 2003;8(1):244-51.

376. Franz M, Janssen P, Lensche H, et al. Effekte stationärer psychoanalytisch orientierter Psychotherapie. Z Psychosom Med Psychother 2000;46(3):242-58.

377. Liebherz S, Rabung S. Do patients' symptoms and interpersonal problems improve in psychotherapeutic hospital treatment in Germany? A systematic review and meta-analysis. PLoS One 2014;9(8):e105329.

378. Schulz H, Harfst T, Härter M. Psychotherapeutische Versorgung bei Menschen mit körperlichen Erkrankungen. Stuttgart: Schattauer; 2015.

379. Steffanowski A, Löschmann C, Schmidt J, et al. Meta-Analyse der Effekte stationärer psychosomatischer Rehabilitation - MESTA-Studie. Bern: Huber; 2007.

380. Härter M, Bermejo I, Deutsche Gesellschaft für Psychiatrie PuND. Rahmenkonzept: Integrierte Versorgung Depression. Der Nervenarzt 2005;76(1):103-21.

381. Büscher C, Rustenbach SJ, Watzke B, et al. KLAR - die Kriterienliste AKUT-REHA. Indikationskriterien für die differenzielle Zuweisung zur Rehabilitation und zur Krankenhausbehandlung für die Psychosomatik. In: Bund DRV, editor. Gesund älter werden - mit Prävention und Rehabilitation. 16. Rehabilitationswissenschaftliches Kolloquium vom 26. bis 28. März 2007 in Berlin. DRV-Schrift Band 72. Berlin: 2006. p. 535-6.

382. Härter M, Bermejo I, Aschenbrenner A, et al. Analyse und Bewertung aktueller Leitlinien zur Diagnostik und Behandlung depressiver Störungen. Fortschr Neurol Psychiatr 2001;69(9):390-401.

383. Heerklotz B. Standard, Richtlinie, Leitlinie, Empfehlung. In: Scheibe O, editor. Qualitätsmanagement in der Medizin. Landsberg: ecomed; 1997. p. 1-3.

384. Helou A, Lorenz W, Ollenschläger G, et al. Methodische Standards der Entwicklung evidenz-basierter Leitlinien in Deutschland. Konsens zwischen Wissenschaft, Selbstverwaltung und Praxis. Z Arztl Fortbild Qualitatssich 2000;94(5):330-9.

385. Klesse C, Barth J, Härter M, et al. Behandlung psychischer Störungen bei koronarer Herzkrankheit. In: Härter M, Baumeister H, Bengel J, editors. Psychische Störungen bei körperlichen Erkrankungen. Berlin: Springer; 2007. p. 97-110.

386. Scogin FR, Hanson A, Welsh D. Self-administered treatment in stepped-care models of depression treatment. J Clin Psychol 2003;59(3):341-9.

387. Bower P, Gilbody S. Stepped care in psychological therapies: access, effectiveness and efficiency. Narrative literature review. Br J Psychiatry 2005;186(1):11-7.

388. Simon GE, Katon WJ, VonKorff M, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001;158(10):1638-44.

389. van Straten A, Tiemens B, Hakkaart L, et al. Stepped care vs. matched care for mood and anxiety disorders: a randomized trial in routine practice. Acta Psychiatr Scand 2006;113(6):468-76.

390. Richards DA, Bower P, Pagel C, et al. Delivering stepped care: an analysis of implementation in routine practice. Implement Sci 2012;7(3):1748-5908.

391. Katon W, Von Korff M, Lin E, et al. Population-based care of depression: effective disease management strategies to decrease prevalence. Gen Hosp Psychiatry 1997;19(3):169-78.

392. Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med 1998;60(2):143-9.

393. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. Jama 1995;273(13):1026-31.

394. Katon W, Robinson P, Von Korff M. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996;53:924-32.

395. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999;56(12):1109-15.

396. van't Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, et al. Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. Arch Gen Psychiatry 2009;66(3):297-304.

397. Bruce ML, Raue PJ, Reilly CF, et al. Clinical effectiveness of integrating depression care management into medicare home health: the Depression CAREPATH randomized trial. JAMA Intern Med 2015;175(1):55-64.

398. Nieuwenhuijsen K, Faber B, Verbeek JH, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev 2014;CD006237.

399. Thota AB, Sipe TA, Byard GJ, et al. Collaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysis. Am J Prev Med 2012;42(5):525-38.

400. van Steenbergen-Weijenburg KM, Feltz-Cornelis CM, Horn EK, et al. Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review. BMC Health Serv Res 2010;10:19.

401. Heddaeus D, Steinmann M, Liebherz S, et al. psychenet - Hamburger Netz psychische Gesundheit: Evaluation des Gesundheitsnetzes Depression aus Sicht der teilnehmenden Hausärzte, Psychotherapeuten und Psychiater. Psychiat Prax 2015;42(S1):S54-S59.

402. Härter M, Berger M. Integrierte Versorgung Depression - Eine gut abgestimmte Behandlung stabilisiert den Erfolg. INFO Neurol Psychiat 2006;8(Sonderheft 1):42-5.

403. Kirchner T, Bergmann F, Engels J, et al. Integrierte Versorgung Depression Aachen. Nervenarzt 2006;77(11):1399-403.

404. Osgood-Hynes DJ, Greist JH, Marks IM, et al. Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: an open U.S.-U.K. study. J Clin Psychiatry 1998;59(7):358-65.

405. Christensen H, Griffiths KM, Korten A. Web-based cognitive behavior therapy: analysis of site usage and changes in depression and anxiety scores. J Med Internet Res 2002;4(1).

406. Proudfoot J, Ryden C, Everitt B, et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004;185(1):46-54.

407. Bundesärztekammer (BÄK). (Muster-) Berufsordnung für die deutschen Ärztinnen und Ärzte (Stand: 2011). 2011.

408. Bundespsychotherapeutenkammer (BPtK). Muster-Berufsordnung für die Psychologischen Psychotherapeutinnen und Psychotherapeuten und Kinder- und Jugendlichenpsychotherapeutinnen und Kinder- und Jugendlichenpsychotherapeuten. 2007 [cited: 2016-09-14]. http://www.bptk.de/uploads/media/20060117_musterberufsordnung.pdf.

409. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (Updated Edition). Leicester: British Psychological Society; 2010.

410. Brown RA, Lewinsohn PM. A psychoeducational approach to the treatment of depression: comparison of group, individual, and minimal contact procedures. J Consult Clin Psychol 1984;52(5):774-83.

411. Lovell K, Bower P, Richards D, et al. Developing guided self-help for depression using the Medical Research Council complex interventions framework: a description of the modelling phase and results of an exploratory randomised controlled trial. BMC Psychiatry 2008;8:91.

412. Bower P, Kontopantelis E, Sutton A, et al. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. Bmj 2013;346:f540.

413. Cuijpers P, Donker T, Johansson R, et al. Self-guided psychological treatment for depressive symptoms: a meta-analysis. PLoS One 2011;6(6):e21274.

414. Houle J, Gascon-Depatie M, Belanger-Dumontier G, et al. Depression self-management support: a systematic review. Patient Educ Couns 2013;91(3):271-9.

415. Selmi PM, Klein MH, Greist JH, et al. Computer-administered cognitive-behavioral therapy for depression. Am J Psychiatry 1990;147(1):51-6.

416. Andersson G, Cuijpers P. Internet-based and other computerized psychological treatments for adult depression: a meta-analysis. Cogn Behav Ther 2009;38(4):196-205.

417. So M, Yamaguchi S, Hashimoto S, et al. Is computerised CBT really helpful for adult depression? A meta-analytic re-evaluation of CCBT for adult depression in terms of clinical implementation and methodological validity. BMC Psychiatry 2013;13(1):113.

418. Arnberg FK, Linton SJ, Hultcrantz M, et al. Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. PLoS One 2014;9(5):e98118.

419. Griffiths KM, Farrer L, Christensen H. The efficacy of internet interventions for depression and anxiety disorders: a review of randomised controlled trials. Med J Aust 2010;192(11 Suppl):S4-11.

420. Moritz S, Schilling L, Hauschildt M, et al. A randomized controlled trial of internet-based therapy in depression. Behav Res Ther 2012;50(7-8):513-21.

421. Meyer B, Berger T, Caspar F, et al. Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. J Med Internet Res 2009;11(2):e15.

422. Berger T, Hammerli K, Gubser N, et al. Internet-based treatment of depression: a randomized controlled trial comparing guided with unguided self-help. Cogn Behav Ther 2011;40(4):251-66.

423. Meyer B, Bierbrodt J, Schröder J, et al. Effects of an Internet intervention (Deprexis) on severe depression symptoms: Randomized controlled trial. Internet Interv 2015;2(1):48-59.

424. Montgomery SA, Roberts A, Patel AG. Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacol 1994;9(Suppl 1):49-53.

425. Collegium Internationale Psychiatriae Scalarum (CIPS), Weyer G. Internationale Skalen für Psychiatrie. Göttingen: Beltz; 2004.

426. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of depression. 2002 [cited: 2016-09-14]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003526.pdf.

427. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. Jama 2002;287(14):1840-7.

428. Oeljeschläger B, Müller-Oerlinghausen B. Wege zur Optimierung der individuellen antidepressiven Therapie. Dtsch Arztebl 2004;101(19):A-1337.

429. Stolk P, Ten Berg MJ, Hemels ME, et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother 2003;37(12):1891-9.

430. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22(1):40-5.

431. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS medicine 2008;5(2):e45.

432. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989;46(11):971-82.

433. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358(3):252-60.

434. Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metab Toxicol 2011;7(2):213-26.

435. Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int Rev Psychiatry 2010;22(5):485-500.

436. Hamilton JA, Grant M, Jensvold MF. Sex and treatment of depression. In: Jensvold MF, Halbreich U, Hamilton JA, editors. Psychopharmacology and women: sex, gender and hormones. Washington: American Psychiatric Association; 1996. p. 241-60.

437. Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 2006;95(1-3):119-23.

438. Martenyi F, Dossenbach M, Mraz K, et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001;11(3):227-32.

439. Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(1):57-65.

440. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157(9):1445-52.

441. National Institute for Clinical Excellence (NICE). Depression: the treatment and management of depression in adults (update). Draft for consultation Feb 2009. 2009 [cited: 2016-09-14]. http://www.nice.org.uk/guidance/cg90/documents/depression-in-adults-update-draft-nice-guideline-for-consultation2.

442. Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003;160(9):1643-50.

443. Papakostas GI, Montgomery SA, Thase ME, et al. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry 2007;68(12):1907-12.

444. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163(11):1905-17.

445. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. Jama 2010;303(1):47-53.

446. Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69(6):572-9.

447. Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 2011;198(1):11-6.

448. Khan A, Sabel MS, Nees A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol 2005;12(9):697-704.

449. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(Suppl 6):39-47.

450. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Eur Psychiatry 1997;12(4):166-76.

451. Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007;68(8):1195-205.

452. Angst J, Stassen HH. Do antidepressants really take several weeks to show effect? In: Leonard BE, editor. Antidepressants. Basel: Birkhäuser; 2001. p. 21-30.

453. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001;4(2):113-8.

454. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005;66(2):148-58.

455. Papakostas GI, Perlis RH, M.J. S, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006;26(1):56-60.

456. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60(12):1228-35.

457. Agid O, Seeman P, Kapur S. The "delayed onset" of antipsychotic action - an idea whose time has come and gone. J Psychiatry Neurosci 2006;31(2):93-100.

458. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005;162(5):939-46.

459. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005;57(12):1543-9.

460. Müller WE. Pharmakologische Grundlagen erwünschter und unerwünschter Wirkungen am Beispiel Antidepressiva. Psychopharmakother 2002;9(1):2-18.

461. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129-44.

462. Storosum JG, Elferink AJ, van Zwieten BJ, et al. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 2001;11(2):173-80.

463. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997;46(3):191-217.

464. Gerson S, Belin TR, Kaufman A, et al. Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. Harv Rev Psychiatry 1999;7(1):1-28.

465. Macgillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Bmj 2003;326(7397):1014.

466. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev 2003;CD003197.

467. Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev 2012;CD009138.

468. Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry 2003;54(3):262-8.

469. Alvarez WJr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003;23(6):754-71.

470. Roose SP, Glassman AH, Siris SG, et al. Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol 1981;1(5):316-9.

471. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Bmj 1995;310(6992):1433-8.

472. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57(4):507-33.

473. Bech P, Cialdella P, Haugh MC, et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000;176(5):421-8.

474. Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000;1(5):917-33.

475. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48(9):894-901.

476. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Jama 2001;286(23):2947-55.

477. Williams JW, Jr., Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132(9):743-56.

478. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie der Depression (Arzneiverordnung in der Praxis). Köln: 2006 [cited: 2016-09-14]. http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/Depression.pdf.

479. Küçükaycan M, Van Den Eede F, Moreels T, et al. Antidepressiva en risico op bloedingen: een literatuuroverzicht. Tijdschr Psychiatr 2012;54:225-34.

480. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163(1):59-64.

481. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Bmj 1999;319(7217):1106-9.

482. Gelenberg AJ. Bleeding with SSRIs. 2005 [cited: 2016-09-14]. http://www.btpnews.com/article/2005/03/01/Bleeding-with-SSRIs.

483. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004;164(21):2367-70.

484. Movig KL, Janssen MW, de Waal MJ, et al. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003;163(19):2354-8.

485. Stingl J, Schmidt LG. Blutungsneigung unter neueren Antidepressiva (SSRI) (Arzneiverordnung in der Praxis). Köln: 1999 [cited: 2016-09-14]. http://www.akdae.de/Arzneimitteltherapie/AVP/Ausgaben/1998-2002/19992.pdf.

486. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007;167(12):1246-51.

487. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007;167(12):1240-5.

488. Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012;27(5):1186-95.

489. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011;108(41):687-93.

490. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Bmj 2010;340:c693.

491. Amrein R, Stabl M, Henauer S, et al. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. Can J Psychiatry 1997;42(10):1043-50.

492. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20(3):226-47.

493. Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord 1995;33(1):1-9.

494. Versiani M, Oggero U, Alterwain P, et al. A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl 1989;155(Suppl 6):72-7.

495. Versiani M, Nardi AE, Mundim FD, et al. Moclobemide, imipramine and placebo in the treatment of major depression. Acta Psychiatr Scand Suppl 1990;360:57-8.

496. Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. Int Clin Psychopharmacol 1997;12(4):183-93.

497. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-78.

498. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand Suppl 1988;78(6):676-83.

499. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148(7):910-6.

500. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53(1):5-11.

501. Müller-Oerlinghausen B, Lasek R, Düppenbecker H, et al. Handbuch der unerwünschten Arzneimittelwirkungen. München: Urban und Fischer; 1999.

502. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997;9(3):157-64.

503. Lecrubier Y, Bourin M, Moon CA, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand Suppl 1997;95(6):485-93.

504. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59(3):116-22.

505. Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11(4):233-6.

506. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60(1):22-8.

507. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997;58(9):393-8.

508. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36(6):383-90.

509. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63(4):308-15.

510. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24(4):389-99.

511. Croft H, Settle J, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21(4):643-58.

512. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11(4):205-15.

513. Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2008.

514. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56(11):519-25.

515. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34(3):165-71.

516. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4(2):145-50.

517. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacology bulletin 1990;26(2):191-6.

518. Fabre LF, Brodie HK, Garver D, et al. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry 1983;44(5 Pt 2):88-94.

519. Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990;51(5):194-9.

520. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003;64(Suppl 5):44-52.

521. Besancon G, Cousin R, Guitton B, et al. Etude en double aveugle de la mianserine et de la fluoxetine chez des patients deprimes traites en ambulatoire. Encephale 1993;19(4):341-5.

522. Brion S, Audrain S, de BC. Episodes depressifs majeurs de sujets ages de plus de 70 ans. Evaluation de l'efficacite et de l'accaptabilite de la tianepine et de la mianserine. Presse Med 1996;25(9):461-8.

523. Dalery J, Aubin V. Etude comparative de la paroxetine et de la mianserine dans la depression du sujet age: efficacite, tolerance, serotoninodependance. Encephale 2001;27(1):71-81.

524. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression. Abschlussbericht. Auftrag A05-20C. Version 1.0. 2009 [cited: 2016-09-14]. http://www.iqwig.de/download/A05-20C_Abschlussbericht_Bupropion_Mirtazapin_und_Reboxetin_bei_Depressionen.pdf.

525. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. Bmj 2010;341:c4737.

526. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67(5):736-46.

527. Laux G. Verträglichkeitsprofil von Agomelatin. Psychopharmakother 2009;(19 Suppl):11-4.

528. Montgomery SA. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 2006;16(Suppl 5):S633-S638.

529. Bauer M, Crossley NA, Gerber S, et al. The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. London: Informa Healthcare; 2006. p. 109-27.

530. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007;68(6):935-40.

531. Kessing LV, Sondergard L, Kvist K, et al. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005;62(8):860-6.

532. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. Bmj 2013;27(346):f3646.

533. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162(10):1805-19.

534. Guzzetta F, Tondo L, Centorrino F, et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007;68(3):380-3.

535. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand Suppl 2001;104(3):163-72.

536. McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379(9817):721-8.

537. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. Bmj 1996;313(7052):253-8.

538. Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Syst Rev 2000;CD000448.

539. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2002;3(2):69-86.

540. Deltito J, Beyer D. The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. J Affect Disord 1998;51(3):345-51.

541. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. Jama 2002;287(14):1807-14.

542. Shelton RC, Keller MB, Gelenberg AJ, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. Jama 2001;285(15):1978-86.

543. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;CD000448.

544. Kolkmann R. Phytopharmaka: Qualität und Vergleich. PZ 1996;141:4424-7.

545. Müller WE. Welches Johanniskrautpräparat soll ich verordnen? Psychopharmakother 2000;7:40.

546. Knuppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. J Clin Psychiatry 2004;65(11):1470-9.

547. Beer AM, Ostermann T. Johanniskraut: Interaktion mit Cyclosporin gefährdet Nierentransplantat und erhöht die täglichen Medikationskosten. Med Klin 2001;96(8):480-3.

548. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999;354(9195):2014-6.

549. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. Jama 2003;290(11):1500-4.

550. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000;355(9203):547-8.

551. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355(9203):548-9.

552. Greeson JM, Sanford B, Monti DA. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001;153(4):402-14.

553. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58(1):19-36.

554. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58.

555. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011;155(11):772-85.

556. Linde K, Kriston L, Rucker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med 2015;13(1):69-79.

557. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(Suppl 1):11-7.

558. Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2003;CD004186.

559. Möller HJ, Glaser K, Leverkus F, et al. Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000;33(6):206-12.

560. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997;6(1):10-8.

561. Menting JE, Honig A, Verhey FR, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 1996;11(3):165-75.

562. Geddes JR, Freemantle N, Mason J, et al. WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 2006;CD001851.

563. Schweizer E, Feighner J, Mandos LA, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55(3):104-8.

564. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51(4):209-13.

565. Samuelian JC, Hackett D. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998;12(3):273-8.

566. Gentil V, Kerr-Correa F, Moreno R, et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000;14(1):61-6.

567. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;259(3):172-85.

568. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011;123(4):247-65.

569. Guaiana G, Gupta S, Chiodo D, et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013;CD008851.

570. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010;25(4):189-98.

571. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011;CD006528.

572. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;CD006532.

573. Angst J. Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials. A meta-analysis of moclobemide trials. Hum Psychopharmacol Clin Exp 1993;8(6):401-7.

574. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol 1995;15(4 Suppl 2):116S-23S.

575. Mulrow CD, Williams J, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000;108(1):54-64.

576. Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004;61(7):714-9.

577. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54(11):1009-15.

578. Hollon SD, DeRubeis RJ, Fawcett J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2014;71(10):1157-64.

579. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342(20):1462-70.

580. Sutej I, Wiethoff K, Neuhaus K, et al. Pharmakotherapie und Psychotherapie bei unipolarer Depression. Ist die kombinierte Behandlung einer Monotherapie überlegen? Z Klin Psychol Psychiatr Psychother 2006;54(3):163-72.

581. Burnand Y, Andreoli A, Kolatte E, et al. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 2002;53(5):585-90.

582. de Jong-Meyer R, Hautzinger M, Rudolf GAE, et al. Die Überprüfung der Wirksamkeit einer Kombination von Antidepressiva- und Verhaltenstherapie bei endogen depressiven Patienten: Varianzanalytische Ergebnisse zu den Haupt- und Nebenkriterien des Therapieerfolgs. Z Klin Psychol Psychother 1996;25(2):93-109.

583. de Jonghe F, Hendriksen M, Van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Br J Psychiatry 2004;185(JULY):37-45.

584. Mynors-Wallis LM, Gath DH, Day A, et al. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. Bmj 2000;320(7226):26-30.

585. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry Suppl 1997;170(2):120-7.

586. Agency for Health Care Policy and Research (AHCPR). Treatment of Depression. Newer Pharmacotherapies. Evidence Report/Technology Assessment No. 7. 1999 [cited: 2016-09-14]. http://www.ncbi.nlm.nih.gov/books/NBK32991.

587. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998;159(10):1245-52.

588. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 2004;37(3):93-7.

589. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004;19(8):754-62.

590. Brambilla P, Cipriani A, Hotopf M, et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 2005;38(2):69-77.

591. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004;37(Suppl 15):S39-S45.

592. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22(3):309-17.

593. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159(11):1896-901.

594. Von Korff M, Goldberg D. Improving outcomes in depression. Bmj 2001;323(7319):948-9.

595. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44(6):195-235.

596. Fritze J, Aldenhoff J, Maier W, et al. Antidepressiva: Lebensgefährliche Placebos? Arznei-Telegramm: fahrlässiges Journal. Nervenarzt 2005;76(11):1432-9.

597. Miller MC. Does the new antidepressant duloxetine (Cymbalta) have any advantages over other antidepressant drugs? Harv Ment Health Lett 2004;21(5):8.

598. Fava GA, Gatti A, Belaise C, et al. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: a Systematic Review. Psychother Psychosom 2015;84(2):72-81.

599. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO, editor. Treatment of psychiatric disorders. 3 ed. Washington: American Psychiatric Publishing; 2001. p. 1417-39.

600. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 1993;54(8 Suppl):39-45.

601. Charney DS, Reynolds III CF, Lewis L, et al. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003;60(7):664-72.

602. Reynolds ICF, Miller MD, Pasternak RE, et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999;156(2):202-8.

603. Reynolds ICF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression. A randomized controlled trial in patients older than 59 years. J Am Med Assoc 1999;281(1):39-45.

604. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44(2):77-87.

605. Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull 2001;57(1):145-59.

606. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27(3):139-45.

607. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;153(Suppl 3):69-76.

608. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8(3):181-8.

609. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13(2):55-62.

610. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(Suppl 1):29-35.

611. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry Suppl 2001;178(4):304-10.

612. Prien RF. Efficacy of continuation drug therapy of depression and anxiety: issues and methodologies. J Clin Psychopharmacol 1990;10(3):86-90.

613. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986;143(1):18-23.

614. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl 2001;179(Suppl 42):S4-S8.

615. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. Arlington: American Psychiatric Association (APA); 2010.

616. Rouillon F, Phillips R, Serrurier D, et al. Rechutes de depression unipolaire et efficacite de la maprotiline. Encephale 1989;15(6):527-34.

617. Greil W, Kleindienst N. Rezidivprophylaxe affektiver Störungen mit Lithium. In: Müller-Oerlinghausen B, Greil W, Berghofer A, editors. Die Lithiumtherapie. Berlin: Springer; 1997. p. 190-218.

618. Reimherr FW, Amsterdam JD, Quitkin FM, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998;155(9):1247-53.

619. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007;62(12):1371-9.

620. Kocsis JH, Kornstein SG, Ahmed S, et al. Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression. Eur Psychiatry 2007;22:S239-S240.

621. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50(1):57-64.

622. Franchini L, Gasperini M, Perez J, et al. Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 1998;59(5):229-32.

623. Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry Suppl 1991;158(5):666-75.

624. Baethge C, Gruschka P, Smolka MN, et al. Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. J Psychiatry Neurosci 2003;28(5):355-61.

625. Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001;CD003013.

626. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57(4):311-7.

627. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160(4):790-2.

628. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Bmj 2005;330(7488):396.

629. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Bmj 2005;330(7488):385.

630. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26(2):203-7.

631. Tondo L, Baldessarini RJ, Floris G, et al. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997;154(4):548-50.

632. Kallner G, Lindelius R, Petterson U, et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000;33(1):8-13.

633. Coppen A. Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry 2000;61(Suppl 9):52-6.

634. Berghofer A, Adli M, Baethge C, et al. Phasenprophylaxe. Hamburg: ConferencePoint Verl.; 2003.

635. Schou M. Suicidal behavior and prophylactic lithium treatment of major mood disorders: a review of reviews. Suicide Life Threat Behav 2000;30(3):289-93.

636. Müller-Oerlinghausen B, Wolf T, Ahrens B, et al. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. Acta Psychiatr Scand Suppl 1994;90(4):295-7.

637. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996;29(3):103-7.

638. Goodwin FK. Anticonvulsant therapy and suicide risk in affective disorders. J Clin Psychiatry 1999;60(Suppl 2):89-93.

639. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47(10):490-4.

640. Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993;28(4):221-31.

641. Dang T, Engel RR. Long-term drug treatment of bipolar and depressive disorders: meta-analysis of controlled trials with lithium, carbamazepime and antidepressive agents. Pharmacopsychiatry 1995;28:170.

642. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013-24.

643. Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004;14(Suppl 2):94-9.

644. Cowen PJ. Pharmacological management of treatment resistant depression. Adv Psychiatr Treat 1998;4:320-7.

645. Thase ME, Rush AJ. Treatment-resistent depression. New York: Raven; 1995.

646. Bauer M, Berghöfer A, Adli M. Akute und therapieresistente Depressionen. Pharmakotherapie-Psychotherapie-Innovationen. 2 ed. Berlin: Springer; 2005.

647. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9(5):442-73.

648. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand Suppl 2001;104(3):173-92.

649. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37(6):243-65.

650. Hiemke C, Dragicevic A, Kuss HJ, et al. TDM zur Optimierung der antidepressiven Pharmakotherapie. Med Welt 2005;56:338-40.

651. Thürmann PA. Geschlechtsspezifische Unterschiede bei Arzneimitteln. Ther Umsch 2007;64(6):325-9.

652. Breitenstein B, Bruckl TM, Ising M, et al. ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2015;4:274-83.

653. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002;161(2):143-51.

654. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255(6):387-400.

655. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006;12(23):2985-92.

656. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19(5):427-34.

657. Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003;48(7):440-8.

658. Bauer M, Whybrow PC, Angst J, et al. Biologische Behandlung unipolarer depressiver Störungen. Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2004.

659. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1519-30.

660. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 1998;59(Suppl 15):35-41.

661. Leff J, Tress K, Edwards B. The clinical course of depressive symptoms in schizophrenia. Schizophrenia Research 1988;1988/01/01(1):25-30.

662. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology bulletin 1989;1989/01/01(3):390-2.

663. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18(2):63-101.

664. Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3- (3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998;43(1):2-11.

665. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;2013/07/03(9896):951-62.

666. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6.

667. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.

668. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS medicine 2013;2013/04/05(3):e1001403.

669. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010;2010/12/15:CD008121.

670. Edwards SJ, Hamilton V, Nherera L, et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health technology assessment 2013;2013/11/29(54):1-190.

671. National Institute for Health and Clinical Excellence (NICE). Depression: the treatment and management of depression in adults (update). 2009 [cited: 2016-09-14]. http://www.nice.org.uk/guidance/CG90.

672. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2013;2013/07/25(5):334-85.

673. Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 2005;20(4):233-8.

674. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23(6):364-72.

675. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand Suppl 2001;103(1):66-72.

676. Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010;121(3):174-9.

677. Romera I, Perez V, Menchon JM, et al. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol 2012;32(4):479-86.

678. Souery D, Serretti A, Calati R, et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2011;12(5):364-75.

679. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51(2):183-8.

680. Dam J, Ryde L, Svejso J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998;31(2):48-54.

681. Debonnel G, Gobbi G, Turcotte J, et al. Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression. Eur Neuropsychopharmacol 2000;10:252.

682. Lauritzen L, Clemmesen L, Klysner R, et al. Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatry 1992;25(4):182-6.

683. Maes M, Libbrecht I, van HF, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999;19(2):177-82.

684. Medhus A, Heskestad S, Tjemsland L. Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone: a randomized, placebo-controlled, double-blind study. Nord J Psychiatry 1994;48(5):355-8.

685. Rocha FL, Fuzikawa C, Riera R, et al. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol 2012;32(2):278-81.

686. Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders - a systematic review. J Affect Disord 2013;144(1-2):1-6.

687. de Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychol Med 1999;29(6):1273-89.

688. Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev 2000;CD001130.

689. von Wolff A, Holzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013;144(1-2):7-15.

690. Kocsis JH, Rush AJ, Markowitz JC, et al. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacology bulletin 2003;37(4):73-87.

691. Michalak EE, Lam RW. Breaking the myths: new treatment approaches for chronic depression. Can J Psychiatry 2002;47(7):635-43.

692. Furukawa T, Streiner DL, Young LT, et al. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2001;CD001026.

693. Wilson K, Mottram P, Sivanranthan A, et al. Antidepressants versus placebo for depressed elderly. Cochrane Database Syst Rev 2001;CD000561.

694. McCusker J, Cole M, Keller E, et al. Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med 1998;158(7):705-12.

695. Hegerl U, Hoff PH. Depressionsbehandlung unter komplizierenden Bedingungen. Komorbidität - Multimedikation - Geriatrische Patienten. Bremen: UNI-MED; 2003.

696. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord 2012;141(2-3):103-15.

697. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006;CD003491.

698. Seitz DP, Gill SS, Conn DK. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2010;25(12):1296-305.

699. Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 2015;63(5):1002-9.

700. Boyce RD, Hanlon JT, Karp JF, et al. A review of the effectiveness of antidepressant medications for depressed nursing home residents. J Am Med Dir Assoc 2012;13(4):326-31.

701. Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 2013;74(6):587-94.

702. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164(6):900-9.

703. Russell J, Raskin J, Wiltse C, et al. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. Psychiatr 2007;4(6):33-45.

704. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999;60(Suppl 20):4-8.

705. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993;94(5A):2S-12S.

706. Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001;9(4):406-14.

707. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. Jama 1998;279(4):287-91.

708. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155(5):660-5.

709. Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 2011;72(12):1660-8.

710. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Bmj 2011;343:d4551.

711. Glassman AH, Bigger J, Giardina EV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979;1(8114):468-72.

712. Glassman AH, Bigger J. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 1981;38(7):815-20.

713. Glassman AH, Walsh BT, Roose SP, et al. Factors related to orthostatic hypotension associated with tricyclic antidepressants. J Clin Psychiatry 1982;43(5 Pt 2):35-8.

714. Coupland N, Wilson S, Nutt D. Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 1997;11(1):83-92.

715. Roose SP. Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. J Clin Psychiatry 2001;62(Suppl 8):19-22.

716. Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging 1994;5(3):192-9.

717. Pollock BG, Mulsant BH, Nebes R, et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998;155(8):1110-2.

718. Mavrogiorgou P, Hegerl U. Neurologische, neuromuskuläre und neurotoxische Effekte der Lithiumbehandlung. In: Müller-Oerlinghausen B, Greil W, Berghöfer A, editors. Die Lithiumbehandlung. Berlin: Springer; 1997. p. 329-41.

719. Böker H, Brandenberger M, Schopper C. Neurotoxische Enzephalopathie unter Kombinationsbehandlung mit Lithium und Risperidon bei einer Patientin mit schizoaffektiver Störung. Psychiatr Prax 2007;34(1):38-41.

720. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000;16(3):165-77.

721. Lord SR, Anstey KJ, Williams P, et al. Psychoactive medication use, sensori-motor function and falls in older women. Br J Clin Pharmacol 1995;39(3):227-34.

722. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316(7):363-9.

723. Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991;151(4):754-6.

724. Ruthazer R, Lipsitz LA. Antidepressants and falls among elderly people in long-term care. Am J Public Health 1993;83(5):746-9.

725. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339(13):875-82.

726. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351(9112):1303-7.

727. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev 2000;CD001312.

728. Reynolds ICF, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006;354(11):1130-8.

729. Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry 2011;168(7):681-8.

730. Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry 2011;19(3):249-55.

731. Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev 2012;CD006727.

732. Wijkstra J, Lijmer J, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2013;CD004044.

733. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 2012;73(4):486-96.

734. Strotzka H. Psychotherapie: Grundlagen, Verfahren, Indikationen. Berlin: Urban und Schwarzenberg; 1975.

735. Roth A, Fonagy P, Parry G, et al. What works for whom? A critical review of psychotherapy research. New York: Guilford Press; 1996.

736. Gloaguen V, Cottraux J, Cucherat M, et al. A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 1998;49(1):59-72.

737. de Rubeis RJ, Gelfand LA, Tang TZ, et al. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 1999;156(7):1007-13.

738. Hollon SD, Munoz RF, Barlow DH, et al. Psychosocial intervention development for the prevention and treatment of depression: Promoting innovation and increasing access. Biol Psychiatry 2002;52(6):610-30.

739. Karasu TB. The specificity versus nonspecificity dilemma: toward identifying therapeutic change agents. Am J Psychiatry 1986;143(6):687-95.

740. Safran JD, Muran JC. Negotiating the therapeutic alliance: a relational treatment guide. New York: Guilford Press; 2000.

741. Norcross JC. Psychotherapy relationships that work: therapist contributions and responsiveness to patients. New York: Oxford University Press; 2002.

742. Schaap C, Bennun I, Schindler L, et al. The therapeutic relationship in behavioural psychotherapy. Oxford: Wiley; 1993.

743. Churchill R, Hunot V, Corney R, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health technology assessment 2001;5(35):1-173.

744. Wampold BE, Minami T, Baskin TW, et al. A meta-(re)analysis of the effects of cognitive therapy versus 'other therapies' for depression. J Affect Disord 2002;68(2-3):159-65.

745. Orlinsky DE, Grawe K, Parks BK. Process and outcome in psychotherapy: Noch einmal. In: Bergin AE, Garfield SL, editors. Bergin and Garfields handbook of psychotherapy and behavior change. Oxford: Wiley; 1994. p. 270-376.

746. Orlinsky DE, Ronnestad MH, Willutzki U. Fifty years of psychtherapy and process-outcome research: continuity and change. In: Lambert MJ, editor. Bergin and Garfields handbook of psychotherapy and behavior change. 5 ed. New York: Wiley; 2004. p. 307-90.

747. Lambert MJ, Ogles BM. The efficacy and effectiveness of psychotherapy. In: Lambert MJ, editor. Bergin and Garfields handbook of psychotherapy and behavior change. 5 ed. New York: Wiley; 2004. p. 139-93.

748. Grawe K. Wie kann Psychotherapie durch Validierung wirksamer werden? Psychotherapeutenj 2005;1(2005):4-11.

749. Grawe K, Donati R, Bernauer F. Psychotherapie im Wandel: Von der Konfession zur Profession. Göttingen: Hogrefe; 1994.

750. Grawe K. Grundriss einer Allgemeinen Psychotherapie. Psychotherapeut 1995;40(3):130-45.

751. Grawe K. "Moderne" Verhaltenstherapie oder allgemeine Psychotherapie? Verhaltenstherapie und Verhaltensmedizin 1997;(18):137-59.

752. Grawe K. Psychologische Therapie. Göttingen: Hogrefe; 1998.

753. Grawe K, Dick A, Regli D, et al. Wirkfaktorenanalyse - ein Spektroskop für die Psychotherapie. Verhaltenstherapie und Psychosoziale Praxis 1999;31(2):201-25.

754. Smith EC, Grawe K. What makes psychotherapy sessions productive? A new approach to bridging the gap between process research and practice. Clin Psychol Psychother 2003;10(5):275-85.

755. Hardy GE, Cahill J, Shapiro DA, et al. Client interpersonal and cognitive styles as predictors of response to time-limited cognitive therapy for depression. J Consult Clin Psychol 2001;69(5):841-5.

756. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1991;148(8):997-1008.

757. Blatt SJ, Sanislow Iii CA, Zuroff DC, et al. Characteristics of effective therapists: further analyses of data from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996;64(6):1276-84.

758. Connolly Gibbons MB, Crits-Christoph P, Levinson J, et al. Flexibility in manual-based psychotherapies: predictors of therapist interventions in interpersonal and cognitive-behavioral therapy. Psychother Res 2003;13(2):169-85.

759. Rector NA, Bagby RM, Segal ZV, et al. Self-criticism and dependency in depressed patients treated with cognitive therapy or pharmacotherapy. Cognit Ther Res 2000;24(5):571-84.

760. Beutler L, Clarkin JF. Systematic treatment selection. New York: Brunner und Mazel; 1990.

761. Faller H. Behandlungserwartungen bei Patienten einer psychotherapeutischen Ambulanz. Psychotherapeut 1998;43(1):8-17.

762. Wilke S, Grande T. Krankheitskonzepte als Verhandlungsgegenstand - ein Modell zur interaktionellen Ausarbeitung von Ursachenvorstellungen in psychoanalytischen Erstinterviews. In: Flick U, editor. Alltagswissen über Gesundheit und Krankheit. Heidelberg: Asanger; 1991. p. 177-97.

763. Blatt SJ, Quinlan DM, Zuroff DC, et al. Interpersonal factors in brief treatment of depression: further analyses of the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996;64(1):162-71.

764. Brown TA, Campbell LA, Lehman CL, et al. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol 2001;110(4):585-99.

765. Lilienfeld SO. Psychological Treatments That Cause Harm. Perspect Psychol Sci 2007;2(1):53-70.

766. Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol 2008;22(1):3-6.

767. Mohr D. Negative outcome in psychotherapy: a Critical Review. Clin Psychol-Sci Pr 1995;2(1):1-27.

768. Shapiro D, Shapiro D. Meta-analysis of comparative therapy outcome studies: a replication and refinement. Psychol Bull 1982;92(3):581-604.

769. Haupt ML, Linden M, Strauß B. Definition und Klassifikation von Psychotherapie Nebenwirkungen. In: Linden M, Strauß B, editors. Risiken und Nebenwirkungen von Psychotherapie - Erfassung, Bewältigung und Risikovermeidung. Berlin: Medizinisch Wissenschaftliche Vertragsgesellschaft; 2012.

770. Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat Psychotherapie? - Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP). Verhaltenstherapie 2014;24:252-63.

771. Nestoriuc Y, Rief W. Risiken und Nebenwirkungen in der Verhaltenstherapie. In: Linden M, Strauß B, editors. Risiken und Nebenwirkungen von Psychotherapie - Erfassung, Bewältigung und Risikovermeidung. Berlin: Medizinisch Wissenschaftliche Vertragsgesellschaft; 2012.

772. Schmoll D. Nebenwirkungen bei psychoanalytisch orientierten Therapien. Psychotherapeut 2012;57(5):395-401.

773. Linden M. How to define, find and classify side effects in psychotherapy: from unwanted events to adverse treatment reactions. Clinical psychology & psychotherapy 2013;20(4):286-96.

774. Beck AT, Rush AJ, Shaw BF, et al. Cognitive therapy of depression. New York: Guilford Press; 1979.

775. Clark DA, Beck AT, Alford BA. Scientific foundations of cognitive theory and therapy of depression. Hoboken: Wiley; 1999.

776. Lewinsohn PM, Munoz R, Youngren MA, et al. Coping with depression. Eugene: Castalia Publishing; 1979.

777. Margraf J, Lieb R. Verhaltenstherapie. In: Freyberger H, Stieglitz R, editors. Kompendium der Psychiatrie und Psychotherapie. Begründet von Th. Spoerri. 10 ed. Basel: Karger; 1996.

778. Beck AT. Depression: clinical, experimental and theoretical aspects. New York: Harper and Row; 1967.

779. Beck J. Praxis der kognitiven Therapie. Weinheim: Beltz; 1999.

780. McCullough J. Treatment for chronic depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP). New York: Guilford Press; 2000.

781. McCullough J. Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP). J Clin Psychol 2003;59(8):833-46.

782. McCullough J. Chronic depression and the Cognitive Behavioral Analysis System of Psychotherapy. In: Stricker G, Gold J, editors. A casebook of psychotherapy integration. Washington: American Psychological Association; 2006. p. 137-51.

783. Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment rherapy: an experiential approach to behavior change. New York: Guilford Press; 1999.

784. Hayes SC, Masuda A, Bassett R, et al. DBT, FAP and ACT: how empirically oriented are the new behaviour therapy technologies? Behav Ther 2004;35(1):35-54.

785. Harris R. Embracing your demons: an overview of acceptance and commitment therapy. Psychother Aust 2006;12:2-8.

786. Williams JMG, RusselI I, Russell D. Mindfulness-based cognitive therapy: further issues in current evidence and future research. J Consult Clin Psychol 2008;76(3):524–9.

787. Klerman GL, Weissman MM, Rounsaville BJ, et al. Interpersonal psychotherapy of depression. New York: Basic Books; 1984.

788. Dykierek P, Schramm E. Interpersonelle Psychotherapie. In: Rössler W, editor. Psychiatrische Rehabilitation. Heidelberg: Springer; 2004. p. 275-92.

789. Schramm E. Interpersonelle Psychotherapie. Stuttgart: Schattauer; 1998.

790. Finke J. Gesprächspsychotherapie. Grundlagen und spezifische Anwendungen. 3 ed. Stuttgart: Thieme; 2004.

791. Speierer GW. Das differentielle Inkongruenzmodell (DIM). Handbuch der Gesprächspsychotherapie als Inkongruenzbehandlung. Heidelberg: Asanger; 1994.

792. Greenberg LS, Rice LN, Elliott R. Facilitating emotional change. The moment-by-moment process. New York: Guilford Press; 1993.

793. Watson JC, Bedard DL. Clients' emotional processing in psychotherapy: A comparison between cognitive-behavioral and process-experiential therapies. J Consult Clin Psychol 2006;74(1):152-9.

794. Watson JC, Gordon LB, Stermac L, et al. Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression. J Consult Clin Psychol 2003;71(4):773-81.

795. Greenberg LS, Watson J. Experiential therapy of depression: differential effects of client-centered relationship conditions and process experiential interventions. Psychother Res 1998;8(2):210-24.

796. Hautzinger M. Depression im Alter. Erkennen, bewältigen, behandeln. Ein kognitiv-verhaltenstherapeutisches Gruppenprogramm. Weinheim: Beltz; 2000.

797. Hautzinger M, Kischkel E. Psychotherapeutisches Behandlungsprogramm für Depression (Handbuch und Materialien). Kompetenznetz Depression; 1999.

798. Herrle J, Kühner C. Depression bewältigen. Ein kognitiv-verhaltenstherapeutisches Gruppenprogramm nach PM Lewinsohn. Weinheim: BeltzPVU; 1994.

799. Ihle W, Herrle J. Stimmungsprobleme bewältigen. Ein kognitiv-verhaltenstherapeutisches Gruppenprogramm zur Prävention, Behandlung und Rückfallprophylaxe depressiver Störungen im Jugendalter nach Clarke und Lewinsohn. Tübingen: Deutsche Gesellschaft für Verhaltenstherapie; 2003.

800. Kühner C, Weber I. Depressionen vorbeugen. Ein Gruppenprogramm nach R. F. Munoz. Göttingen: Hogrefe; 2001.

801. Beach SRH. Marital and family processes in depression: a scientific foundation for clinical practice. Washington, DC: American Psychological Association (APA); 2001.

802. Bodenmann G. Stress und Coping bei Paaren. Göttingen: Hogrefe; 2000.

803. Beach SR, Sandeen EE, O'Leary KD. Depression and marriage. New York: Guilford Press; 1990.

804. Jacobson NS, Dobson K, Fruzzetti AE, et al. Marital therapy as a treatment for depression. J Consult Clin Psychol 1991;59(4):547-57.

805. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006;74(4):658-70.

806. Hardy GE, Cahill J, Stiles WB, et al. Sudden gains in cognitive therapy for depression: a replication and extension. J Consult Clin Psychol 2005;73(1):59-67.

807. Longmore RJ, Worrell M. Do we need to challenge thoughts in cognitive behavior therapy? Clin Psychol Rev 2007;27(2):173-87.

808. Hautzinger M, de Jong-Meyer R, Treiber R, et al. Wirksamkeit Kognitiver Verhaltenstherapie, Pharmakotherapie und deren Kombination bei nicht-endogenen, unipolaren Depressionen. Z Klin Psychol Psychother 1996;25(2):130-45.

809. Cape J, Whittington C, Buszewicz M, et al. Brief psychological therapies for anxiety and depression in primary care: meta-analysis and meta-regression. BMC Med 2010;8:38.

810. Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2010;40(2):211-23.

811. Cuijpers P, Clignet F, van Meijel B, et al. Psychological treatment of depression in inpatients: a systematic review and meta-analysis. Clin Psychol Rev 2011;31(3):353-60.

812. Cuijpers P. A psychoeducational approach to the treatment of depression: a meta- analysis of Lewinsohn's 'Coping With Depression' course. Behav Ther 1998;29(3):521-33.

813. McDermut W, Miller IW, Brown RA. The efficacy of group psychotherapy for depression: a meta-analysis and review of the empirical research. Clin Psychol-Sci Pr 2001;8(1):98-116.

814. Toseland RW, Siporin M. When to recommend group treatment: A review of the clinical and the research literature. Int J Group Psychother 1986;36(2):171-201.

815. Vander-Voort DJ, Fuhriman A. The efficacy of group therapy for depression: a review of the literature. Small Gr Res 1991;22(3):320-38.

816. Ihle W, Jahnke D, Spieß L, et al. Evaluation eines kognitiv-verhaltenstherapeutischen Gruppenprogramms für depressive Jugendliche und junge Erwachsene. Kindh Entwickl 2002;11(4):238-47.

817. Ayen I, Hautzinger M. Kognitive Verhaltenstherapie bei Depressionen im Klimakterium: Eine kontrollierte, randomisierte Interventionsstudie. Z Klin Psychol Psychother 2004;33(4):290-9.

818. Hautzinger M, Welz S, Utzeri S. Gruppen- oder Einzelpsychotherapie bei Depressionen im Alter. Ergebnisse einer randomisierten, kontrollierten Vergleichsstudie. Unveröffentlichter Forschungsbericht. Tübingen: Universität Tübingen; 2005.

819. Kühner C, Angermeyer MC, Veiel HO. Cognitive-behavioral group intervention as a means of tertiary prevention in depressed patients: Acceptance and short-term efficacy. Cognit Ther Res 1996;20(4):391-409.

820. Huntley AL, Araya R, Salisbury C. Group psychological therapies for depression in the community: systematic review and meta-analysis. Br J Psychiatry 2012;200(3):184-90.

821. Bolton P, Bass J, Neugebauer R, et al. Group interpersonal psychotherapy for depression in rural uganda: a randomized controlled trial. J Am Med Assoc 2003;289(23):3117-24.

822. Wahl R. Kurzpsychotherapie bei Depressionen. Interpersonelle Psychotherapie und kognitive Therapie im Vergleich. Opladen: Westdeutscher Verlag; 1994.

823. Barbato A, D’Avanzo BBD. Marital therapy for depression. Cochrane Database Syst Rev 2006;CD004188.

824. Henken T, Huibers MJ, Churchill R, et al. Family therapy for depression. Cochrane Database Syst Rev 2007;CD006728.

825. de Rubeis RJ, Crits-Christoph P. Empirically supported individual and group psychological treatments for adult mental disorders. J Consult Clin Psychol 1998;66(1):37-52.

826. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005;62(4):417-22.

827. Dobson KS. A meta-analysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 1989;57(3):414-9.

828. Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 1995;63(6):966-80.

829. Spielmans GI, Berman MI, Usitalo AN. Psychotherapy versus second-generation antidepressants in the treatment of depression: a meta-analysis. J Nerv Ment Dis 2011;199(3):142-9.

830. Tolin DF. Is cognitive-behavioral therapy more effective than other therapies?: A meta-analytic review. Clin Psychol Rev 2010;30(6):710-20.

831. Leichsenring F, Klein S, Salzer S. The efficacy of psychodynamic psychotherapy in specific mental disorders: a 2013 update of empirical evidence. Contemporary Psychoanalysis 2014;50(1-2):89-130.

832. Shinohara K, Honyashiki M, Imai H, et al. Behavioural therapies versus other psychological therapies for depression. Cochrane Database Syst Rev 2013;CD008696.

833. Mazzucchelli T, Kane R, Rees C. Behavioral Activation Treatments for Depression in Adults: a Meta-analysis and Review. Clin Psychol-Sci Pr 2009;16(4):383-411.

834. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS medicine 2013;10(5):e1001454.

835. Ebrahim S, Montoya L, Truong W, et al. Effectiveness of cognitive behavioral therapy for depression in patients receiving disability benefits: a systematic review and individual patient data meta-analysis. PLoS One 2012;7(11):e50202.

836. Hans E, Hiller W. Effectiveness of and dropout from outpatient cognitive behavioral therapy for adult unipolar depression: a meta-analysis of nonrandomized effectiveness studies. J Consult Clin Psychol 2013;81(1):75-88.

837. Hunot V, Moore THM, Caldwell DM, et al. ’Third wave’ cognitive and behavioural therapies versus other psychological therapies for depression. Cochrane Database Syst Rev 2013;CD008704.

838. Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol 2010;78(2):169-83.

839. Strauss C, Cavanagh K, Oliver A, et al. Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder: a meta-analysis of randomised controlled trials. PLoS One 2014;9(4):e96110.

840. Crits-Christoph P. The efficacy of brief dynamic psychotherapy: a meta-analysis. Am J Psychiatry 1992;149(2):151-8.

841. Leichsenring F. Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: a meta-analytic approach. Clin Psychol Rev 2001;21(3):401-19.

842. Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 2004;61(12):1208-16.

843. Thompson LW, Gallagher D, Breckenridge JS. Comparative effectiveness of psychotherapies for depressed elders. J Consult Clin Psychol 1987;55(3):385-90.

844. Cooper PJ, Murray L, Wilson A, et al. Controlled trial of the short- and long-term effect of psychological treatment of post-partum depression. I. Impact on maternal mood. Br J Psychiatry 2003;182(MAY):412-9.

845. Leichsenring F. Are psychodynamic and psychoanalytic therapies effective? A review of empirical data. Int J Psychoanal 2005;86(3):841-68.

846. Abbass AA, Kisely SR, Town JM, et al. Short-term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev 2014;CD004687.

847. Driessen E, Cuijpers P, de Maat S, et al. The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. Clin Psychol Rev 2010;30(1):25-36.

848. Leichsenring F, Leweke F, Klein S, et al. The empirical status of psychodynamic psychotherapy - an update: bambi's alive and kicking. Psychother Psychosom 2015;84(3):129-48.

849. Brockmann J, Schlüter T, Eckert J. Langzeitwirkungen psychoanalytischer und verhaltenstherapeutischer Langzeittherapien. Eine vergleichende Studie aus der Praxis niedergelassener Psychotherapeuten. Psychother Psychosom Med 2006;51:15-25.

850. Leichsenring F, Biskup J, Kreische R, et al. The Gottingen study of psychoanalytic therapy: first results. Int J Psychoanal 2005;86(2):433-55.

851. Leuzinger-Bohrleber M, Stuhr U, Rüger B, et al. Langzeitwirkungen von Psychoanalysen und Psychotherapien: Eine multiperspektivische, repräsentative Katamnesestudie. Psyche 2001;55(3):193-276.

852. Rudolf G, Grande T, Dilg R, et al. Effektivität und Effizienz psychoanalytischer Langzeittherapie: Die Praxisstudie analytische Langzeittherapie. In: Gerlach A, Schlösser A, Springer A, editors. Psychoanalyse des Glaubens. Gießen: Psychosozial-Verl; 2004. p. 515-28.

853. Grande T, Dilg R, Jakobsen T, et al. Differential effects of two forms of psychoanalytic therapy: results of the Heidelberg-Berlin study. Psychother Res 2006;16(4):470-85.

854. Jacobsen T, Rudolf G, Brockmann J, et al. Ergebnisse analytischer Langzeitpsychotherapien bei spezifischen psychischen Störungen: Verbesserungen in der Symptomatik und in interpersonellen Beziehungen. Z Psychosom Med Psychother 2007;53(2):87-110.

855. Huber D, Klug G. Munich Psychotherapy Study (MPS): Preliminary results on process and outcome of psychoanalytic psychotherapy - a prospective psychotherapy study with depressed patients. Psychother Psychosom Med 2005;55:101.

856. Sandell R, Blomberg J, Lazar A. Wiederholte Langzeitkatamnesen von Langzeitpsychotherapien und Psychoanalysen. Z Psychosom Med Psychother 1999;45(1):43-56.

857. Sandell R, Blomberg J, Lazar A, et al. Unterschiedliche Langzeitergebnisse von Psychoanalysen und Langzeitpsychotherapien. Aus der Forschung des Stockholmer Psychoanalyse- und Psychotherapieprojekts. Psyche 2001;55(3):273-310.

858. Huber D, Zimmermann J, Henrich G, et al. Comparison of cognitive-behaviour therapy with psychoanalytic and psychodynamic therapy for depressed patients - a three-year follow-up study. Z Psychosom Med Psychother 2012;58(3):299-316.

859. de Maat S, de Jonghe F, de Kraker R, et al. The current state of the empirical evidence for psychoanalysis: a meta-analytic approach. Harv Rev Psychiatry 2013;21(3):107-37.

860. Knekt P, Lindfors O, Harkanen T, et al. Randomized trial on the effectiveness of long-and short-term psychodynamic psychotherapy and solution-focused therapy on psychiatric symptoms during a 3-year follow-up. Psychol Med 2008;38(5):689-703.

861. Knekt P, Lindfors O, Sares-Jaske L, et al. Randomized trial on the effectiveness of long- and short-term psychotherapy on psychiatric symptoms and working ability during a 5-year follow-up. Nord J Psychiatry 2013;67(1):59-68.

862. Leff J, Vearnals S, Brewin CR, et al. The London depression intervention trial. Randomised controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: clinical outcome and costs. Br J Psychiatry 2000;177(Aug):95-100.

863. Seikkula J, Aaltonen J, Kalla O, et al. Couple therapy for depression in a naturalistic setting in finland: a 2-year randomized trial. J Fam Ther 2013;35(3):281-302.

864. American Psychiatric Association (APA). The practice of electroconvulsive therapy: recommendations for treatment, training and privileging: a task force report of the American Psychiatric Association. Washington: American Psychiatric Association (APA); 2001.

865. Balslev Jorgensen M, Dam H, Bolwig TG. The efficacy of psychotherapy in non-bipolar depression: a review. Acta Psychiatr Scand 1998;98(1):1-13.

866. Feijo De Mello M, de Jesus Mari J, Bacaltchuk J, et al. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 2005;255(2):75-82.

867. Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: a meta-analysis. Am J Psychiatry 2011;168(6):581-92.

868. van Hees ML, Rotter T, Ellermann T, et al. The effectiveness of individual interpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a systematic review. BMC Psychiatry 2013;13:22.

869. Elliott R, Greenberg LS, Lietaer G. Research on experiential psychotherapies. In: Lambert MJ, editor. Bergin and Garfields handbook of psychotherapy and behavior change. 5 ed. New York: Wiley; 2004. p. 493-540.

870. Chambless DL, Hollon SD. Defining empirically supported therapies. J Consult Clin Psychol 1998;66(1):7-18.

871. King M, Sibbald B, Ward E, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health technology assessment 2000;4(19):1-83.

872. Meyer A. Das Hamburger Kurzpsychotherapie-Vergleichsexperiment. Psychother Psychosom 1981;35:81-207.

873. Meyer A, Stuhr U, Wirth U, et al. 12-Year follow-up study of the Hamburg short psychotherapy experiment: an overview. Psychother Psychosom 1988;50(4):192-200.

874. Teusch L, Bohme H, Finke J, et al. Antidepressant medication and the assimilation of problematic experiences in psychotherapy. Psychother Res 2003;13(3):307-22.

875. Teusch L, Bohme H, Finke J, et al. Effects of client-centered psychotherapy for personality disorders alone and in combination with psychopharmacological treatment: an empirical follow-up study. Psychother Psychosom 2001;70(6):328-36.

876. Watson JC, Greenberg LS. Pathways to change in the psychotherapy of depression: Relating process to session change and outcome. Psychotherapy 1996;33(2):262-74.

877. Pos AE, Greenberg LS, Goldman RN, et al. Emotional processing during experiential treatment of depression. J Consult Clin Psychol 2003;71(6):1007-16.

878. de Maat S, Dekker J, Schoevers R, et al. Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Psychother Res 2006;16(5):566-78.

879. Blackburn IM, Bishop S, Glen AI, et al. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981;139(3):181-9.

880. Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997;171(OCT.):328-34.

881. Murphy GE, Simons AD, Wetzel RD, et al. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Arch Gen Psychiatry 1984;41(1):33-41.

882. Jarrett RB, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56(5):431-7.

883. Weissman MM, Prusoff BA, Dimascio A, et al. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 1979;136(4B):555-8.

884. Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 1996;53(10):913-9.

885. Shapiro DA, Barkham M, Rees A, et al. Effects of treatment duration and severity of depression on the effectiveness of cognitive-behavioral and psychodynamic-interpersonal psychotherapy. J Consult Clin Psychol 1994;62(3):522-34.

886. de Jonghe F, Kool S, Van Aalst G, et al. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001;64(2-3):217-29.

887. Ward E, King M, Lloyd M, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: Clinical effectiveness. Bmj 2000;321(7273):1383-8.

888. de Rubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62(4):409-16.

889. Frank E, Spanier C. Interpersonal psychotherapy for depression: overview, clinical efficacy, and future directions. Clin Psychol-Sci Pr 1995;2(4):349-69.

890. Markowitz JC. Psychotherapy of dysthymia. Am J Psychiatry 1994;151(8):1114-21.

891. Cuijpers P, van Straten A, Schuurmans J, et al. Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin Psychol Rev 2010;30(1):51-62.

892. von Wolff A, Hölzel LP, Westphal A, et al. Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: a systematic review and meta-analysis. BMC Psychiatry 2012;12(1):61.

893. Kriston L, von Wolff A, Westphal A, et al. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety 2014;31(8):621-30.

894. Kocsis JH, Gelenberg AJ, Rothbaum BO, et al. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry 2009;66(11):1178-88.

895. Imel ZE, Malterer MB, McKay KM, et al. A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia. J Affect Disord 2008;110(3):197-206.

896. Segal ZV, Whitney DK, Lam RW. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry 2001;46(Suppl 1):29S-37S.

897. Ravindran AV, Anisman H, Merali Z, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. Am J Psychiatry 1999;156(10):1608-17.

898. Dunner DL, Schmaling KB, Hendrickson H, et al. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression 1996;4(1):34-41.

899. Williams J, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. J Am Med Assoc 2000;284(12):1519-26.

900. Browne G, Steiner M, Roberts J, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-Month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002;68(2-3):317-30.

901. Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord 2005;89(1-3):167-75.

902. Miller IW, Norman WH, Keitner GI. Combined treatment for patients with double depression. Psychother Psychosom 1999;68(4):180-5.

903. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.[Erratum appears in Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16530. Proc Natl Acad Sci U S A 2003;100(24):14293-6.

904. Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: Medication (Nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005;62(5):513-20.

905. Peng XD, Huang CQ, Chen LJ, et al. Cognitive behavioural therapy and reminiscence techniques for the treatment of depression in the elderly: a systematic review. J Int Med Res 2009;37(4):975-82.

906. Wilson KC, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older depressed people. Cochrane Database Syst Rev 2008;CD004853.

907. Kiosses DN, Leon AC, Arean PA. Psychosocial interventions for late-life major depression: evidence-based treatments, predictors of treatment outcomes, and moderators of treatment effects. Psychiatr Clin North Am 2011;34(2):377-401.

908. Gould RL, Coulson MC, Howard RJ. Cognitive behavioral therapy for depression in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc 2012;60(10):1817-30.

909. Francis JL, Kumar A. Psychological treatment of late-life depression. Psychiatr Clin North Am 2013;36(4):561-75.

910. Krishna M, Honagodu A, Rajendra R, et al. A systematic review and meta-analysis of group psychotherapy for sub-clinical depression in older adults. Int J Geriatr Psychiatry 2013;28(9):881-8.

911. Ermann M, Waldvogel B. Psychodynamische Psychotherapie - Grundlagen und klinische Anwendungen. Berlin: Springer; 2011.

912. Yon A, Scogin F. Behavioural activation as a treatment for geriatric depression. Clin Gerontol 2009;32:91-103.

913. Arean PA. Problem-solving therapy. Psychiatr Ann 2009;39:854-62.

914. Hautzinger M, Welz S. Kognitive Verhaltenstherapie bei Depressionen im Alter - Ergebnisse einer kontrollierten Vergleichsstudie unter ambulanten Bedingungen an Depressionen mittleren Schweregrads. Z Gerontol Geriatr 2004;37(6):427-35.

915. Hautzinger M, Welz S. Kurz- und längerfristige Wirksamkeit psychologischer Interventionen bei Depressionen im Alter. Z Klin Psychol Psychother 2008;37(1):52-60.

916. Cody RA, Drysdale K. The effects of psychotherapy on reducing depression in residential aged care: a meta-analytic review. Clinical Gerontol 2013;36(1):46-69.

917. Payne KT, Marcus DK. The efficacy of group psychotherapy for older adult clients: a meta-analysis. Group Dyn 2008;12(4):268-78.

918. Lee SY, Franchetti MK, Imanbayev A, et al. Non-pharmacological prevention of major depression among community-dwelling older adults: a systematic review of the efficacy of psychotherapy interventions. Arch Gerontol Geriatr 2012;55(3):522-9.

919. Cuijpers P, Reynolds CF, III, Donker T, et al. Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depress Anxiety 2012;29(10):855-64.

920. Conte HR, Plutchik R, Wild KV, et al. Combined psychotherapy and pharmacotherapy for depression. A systematic analysis of the evidence. Arch Gen Psychiatry 1986;43(5):471-9.

921. Friedman MA, Detweiler-Bedell JB, Leventhal HE. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clin Psychol 2004;11(1):47-68.

922. Hautzinger M. Psychotherapie und Pharmakotherapie bei Depressionen. Psychotherapeut 1995;40(6):373-80.

923. Jindal RD, Thase ME. Integrating psychotherapy and pharmacotherapy to improve outcomes among patients with mood disorders. Psychiatr Serv 2003;54(11):1484-90.

924. Wexler BE, Cicchetti DV. The outpatient treatment of depression. Implications of outcome research for clinical practice. J Nerv Ment Dis 1992;180(5):277-86.

925. Cuijpers P, van Straten A, Hollon SD, et al. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. Acta Psychiatr Scand 2010;121(6):415-23.

926. Cuijpers P, van Straten A, Warmerdam L, et al. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety 2009;26(3):279-88.

927. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 1995;25(6):1171-80.

928. Frank E, Kupfer DJ, Wagner EF, et al. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: Contributing factors. Arch Gen Psychiatry 1991;48(12):1053-9.

929. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S.

930. Simons AD, Murphy GE, Levine JL, et al. Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. Arch Gen Psychiatry 1986;43(1):43-8.

931. Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up: findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992;49(10):782-7.

932. Evans MD, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992;49(10):802-8.

933. Vittengl JR, Clark LA, Dunn TW, et al. Reducing Relapse and Recurrence in Unipolar Depression: a Comparative Meta-Analysis of Cognitive-Behavioral Therapy's Effects. J Consult Clin Psychol 2007;75(3):475-88.

934. Beck AT. The current state of cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry 2005;62(9):953-9.

935. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. A controlled trial. Arch Gen Psychiatry 1999;56(9):829-35.

936. Galante J, Iribarren SJ, Pearce PF. Effects of mindfulness-based cognitive therapy on mental disorders: a systematic review and meta-analysis of randomised controlled trials. J Res Nurs 2013;18(2):133-55.

937. Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev 2011;31(6):1032-40.

938. Clarke K, Mayo-Wilson E, Kenny J, et al. Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. Clin Psychol Rev 2015;39:58-70.

939. Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994;151(9):1295-9.

940. Fava GA, Grandi S, Zielezny M, et al. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996;153(7):945-7.

941. Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998;155(10):1443-5.

942. Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: Preliminary findings. Arch Gen Psychiatry 1998;55(9):816-20.

943. Jarrett RB, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001;58(4):381-8.

944. Bockting CL, Schene AH, Spinhoven P, et al. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol 2005;73(4):647-57.

945. Teasdale JD, Segal ZV, Williams JMG, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68(4):615-23.

946. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004;72(1):31-40.

947. Klein DN, Santiago NJ, Vivian D, et al. Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol 2004;72(4):681-8.

948. Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002;22(5):474-80.

949. Frank E, Grochocinski VJ, Spanier CA, et al. Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry 2000;61(1):51-7.

950. Paykel ES. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2007;10(1):131-6.

951. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. J Am Med Assoc 2001;285(10):1299-307.

952. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9(1-2):83-91.

953. Moore RG, Blackburn IM. Cognitive therapy in the treatment of non-responders to antidepressant medication: a controlled pilot study. Behav Cogn Psychother 1997;25(3):251-9.

954. Harpin RE, Liberman RP, Marks I, et al. Cognitive-behavior therapy for chronically depressed patients. A controlled pilot study. J Nerv Ment Dis 1982;170(5):295-301.

955. Bristow M, Bright J. Group cognitive therapy in chronic depression: Results from two intervention studies. Behav Cogn Psychother 1995;23(4):373-80.

956. Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: results of a treatment regime. Int Clin Psychopharmacol 1987;2(3):261-72.

957. McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005;111(5):331-40.

958. Trivedi RB, Nieuwsma JA, Williams JW. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med 2011;26(6):643-50.

959. Kendler KS, Gardner CO. Sex differences in the pathways to major depression: a study of opposite-sex twin pairs. Am J Psychiatry 2014;171(4):426-35.

960. Weissman MM. Treatment of depression: men and women are different? Am J Psychiatry 2014;171(4):384-7.

961. Fournier JC, DeRubeis RJ, Shelton RC, et al. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 2009;77(4):775-87.

962. Hoberman HM, Lewinsohn PM, Tilson M. Group treatment of depression: individual predictors of outcome. J Consult Clin Psychol 1988;56(3):393-8.

963. Jarrett RB, Eaves GG, Grannemann BD, et al. Clinical, cognitive, and demographic predictors of response to cognitive therapy for depression: a preliminary report. Psychiatry Res 1991;37(3):245-60.

964. Thase ME, Reynolds ICF, Frank E, et al. Do depressed men and women respond similarly to cognitive behavior therapy? Am J Psychiatry 1994;151(4):500-5.

965. Schneider D, Zobel I, Härter M, et al. Wirkt die Interpersonelle Psychotherapie besser bei Frauen als bei Männern? Ergebnisse einer randomisierten, kontrollierten Studie. Psychother Psychosom Med 2008;58(1):23-31.

966. Parker G, Blanch B, Crawford J. Does gender influence response to differing psychotherapies by those with unipolar depression? J Affect Disord 2011;130(1-2):17-20.

967. McHugh RK, Whitton SW, Peckham AD, et al. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry 2013;74(6):595-602.

968. Braun SR, Gregor B, Tran US. Comparing bona fide psychotherapies of depression in adults with two meta-analytical approaches. PLoS One 2013;8(6):e68135.

969. Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst 2012;104(13):990-1004.

970. Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013;75(4):335-49.

971. Pinquart M, Forstmeier S. Effects of reminiscence interventions on psychosocial outcomes: a meta-analysis. Aging Ment Health 2012;16(5):541-58.

972. Cuijpers P, Weitz E, Twisk J, et al. Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. Depress Anxiety 2014;31(11):941-51.

973. The UK ECT review group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361(9360):799-808.

974. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001;17(4):244-53.

975. Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry 2005;162(5):977-82.

976. Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord 2001;63(1-3):1-15.

977. Nobler MS, Sackeim HA. Electroconvulsive therapy. In: Helmchen H, Henn F, Lauter H, et al, editors. Contemporary psychiatry. 3 ed. Berlin: Springer; 2000. p. 425-34.

978. Pagnin D, de Queiroz V, Pini S, et al. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004;20(1):13-20.

979. Wissenschaftlicher Beirat dB. Stellungnahme zur Elektrokrampftherapie (EKT) als psychiatrische Behandlungsmaßnahme. Dtsch Arztebl 2003;100(8):504-6.

980. Kellner CH, Popeo DM, Pasculli RM, et al. Appropriateness for electroconvulsive therapy (ECT) can be assessed on a three-item scale. Med Hypotheses 2012;79(2):204-6.

981. Rhebergen D, Huisman A, Bouckaert F, et al. Older age is associated with rapid remission of depression after electroconvulsive therapy: a latent class growth analysis. Am J Geriatr Psychiatry 2015;23(3):274-82.

982. Flint AJ, Gagnon N. Effective use of electroconvulsive therapy in late-life depression. Can J Psychiatry 2002;47(8):734-41.

983. Dombrovski AY, Mulsant BH. The evidence for electroconvulsive therapy (ECT) in the treatment of severe late-life depression. ECT: the preferred treatment for severe depression in late life. Int Psychogeriatr 2007;19(1):10-35.

984. van der Wurff FB, Stek ML, Hoogendijk WJ, et al. The efficacy and safety of ECT in depressed older adults: a literature review. Int J Geriatr Psychiatry 2003;18(10):894-904.

985. van der Wurff FB, Stek ML, Hoogendijk WL, et al. Electroconvulsive therapy for the depressed elderly. Cochrane Database Syst Rev 2003;CD003593.

986. Loh N, Nickl-Jockschat T, Sheldrick AJ, et al. Accessibility, standards and challenges of electroconvulsive therapy in Western industrialized countries: a German example. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2013;14(6):432-40.

987. Grözinger M, Conca A, Nickl-Jockschat T, et al. Elektrokonvulsionstherapie kompakt. Für Zuweiser und Anwender. Heidelberg: Springer; 2013.

988. Grözinger M, Conca A, DiPauli J, et al. Elektrokonvulsionstherapie: Psychiatrische Fachgesellschaften aus vier Ländern empfehlen einen rechtzeitigen und adäquaten Einsatz. Nervenarzt 2012;83:919-21.

989. Pfaff M, Seidl A, Angst K, et al. Elektrokonvulsionstherapie als Ultima Ratio in der Behandlung der Depression? Psychiatr Prax 2013;40(7):385-90.

990. Tölle R. Nicht die Elektrokrampftherapie, sondern ihre Gegner stehen in der Kritik. Nervenarzt 2008;79(11):1310-2.

991. Sackeim HA. Repetitive transcranial magnetic stimulation: what are the next steps? Biol Psychiatry 2000;48(10):959-61.

992. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993;328(12):839-46.

993. Shapira B, Tubi N, Drexler H, et al. Cost and benefit in the choice of ECT schedule. Twice versus three times weekly ECT. Br J Psychiatry Suppl 1998;172(1):44-8.

994. Swartz CM. Electroconvulsive therapy and neuromodulation therapies. New York: Cambridge University Press; 2009.

995. Fink M, Abrams R, Bailine S, et al. Ambulatory electroconvulsive therapy: report of a task force of the association for convulsive therapy. Association for Convulsive Therapy. Convuls Ther 1996;12(1):42-55.

996. Ottosson JO. Experimental studies of the mode of action of electroconvulsive therapy: introduction. Acta Psychiatr Scand Suppl 1960;35(145):5-6.

997. Kondratyev A, Ved R, Gale K. The effects of repeated minimal electroconvulsive shock exposure on levels of mRNA encoding fibroblast growth factor-2 and nerve growth factor in limbic regions. Neuroscience 2002;114(2):411-6.

998. Madsen TM, Treschow A, Bengzon J, et al. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry 2000;47(12):1043-9.

999. Piccinni A, Del Debbio A, Medda P, et al. Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009;19(5):349-55.

1000. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;20(24):9104-10.

1001. Devanand DP, Dwork AJ, Hutchinson ER, et al. Does ECT alter brain structure? Am J Psychiatry 1994;151(7):957-70.

1002. Wijeratne C, Halliday GS, Lyndon RW. The present status of electroconvulsive therapy: a systematic review. Med J Aust 1999;171(5):250-4.

1003. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990;31(3):287-96.

1004. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996;153(8):985-92.

1005. Bourgon LN, Kellner CH. Relapse of depression after ECT: a review. J ECT 2000;16(1):19-31.

1006. Sackeim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990;10(2):96-104.

1007. Lauritzen L, Odgaard K, Clemmesen L, et al. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 1996;94(4):241-51.

1008. Mayur PM, Gangadhar BN, Subbakrishna DK, et al. Discontinuation of antidepressant drugs during electroconvulsive therapy: a controlled study. J Affect Disord 2000;58(1):37-41.

1009. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994;151(2):169-76.

1010. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry 2010;68(6):568-77.

1011. Lisanby SH, Maddox JH, Prudic J, et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 2000;57(6):581-90.

1012. Devanand DP, Fitzsimons L, Prudic J, et al. Subjective side effects during electroconvulsive therapy. Convuls Ther 1995;11(4):232-40.

1013. Brakemeier EL, Merkl A, Wilbertz G, et al. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biol Psychiatry 2014;76(3):194-202.

1014. Frederikse M, Petrides G, Kellner C. Continuation and maintenance electroconvulsive therapy for the treatment of depressive illness: a response to the National Institute for Clinical Excellence report. J ECT 2006;22(1):13-7.

1015. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001;25(5):713-28.

1016. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology 2013;38(12):2467-74.

1017. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63(12):1337-44.

1018. Brown ED, Lee H, Scott D, et al. Efficacy of continuation/maintenance electroconvulsive therapy for the prevention of recurrence of a major depressive episode in adults with unipolar depression: a systematic review. J ECT 2014;30(3):195-202.

1019. Petrides G, Tobias KG, Kellner CH, et al. Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature. Neuropsychobiology 2011;64(3):129-40.

1020. Rabheru K, Persad E. A review of continuation and maintenance electroconvulsive therapy. Can J Psychiatry 1997;42(5):476-84.

1021. Kuhs H, Farber D, Tolle R. Serum prolactin, growth hormone, total corticoids, thyroid hormones and thyrotropine during serial therapeutic sleep deprivation. Biol Psychiatry 1996;39(10):857-64.

1022. Pflug B. The influence of sleep deprivation on the duration of endogenous depressive episodes. Arch Psychiatr Nervenkr 1978;225(2):173-7.

1023. van den Hoofdakker RH. Chronobiological theories of nonseasonal affective disorders and their implications for treatment. J Biol Rhythms 1994;9(2):157-83.

1024. Leibenluft E, Wehr TA. Is sleep deprivation useful in the treatment of depression? Am J Psychiatry 1992;149(2):159-68.

1025. Kuhs H, Tolle R. Sleep deprivation therapy. Biol Psychiatry 1991;29(11):1129-48.

1026. Wirz-Justice A, van den Hoofdakker RH. Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 1999;46(4):445-53.

1027. Wiegand MH, Lauer CJ, Schreiber W. Patterns of response to repeated total sleep deprivations in depression. J Affect Disord 2001;64(2-3):257-60.

1028. Riemann D, Konig A, Hohagen F, et al. How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay. Eur Arch Psychiatry Clin Neurosci 1999;249(5):231-7.

1029. Voderholzer U, Valerius G, Schaerer L, et al. Is the antidepressive effect of sleep deprivation stabilized by a three day phase advance of the sleep period? A pilot study. Eur Arch Psychiatry Clin Neurosci 2003;253(2):68-72.

1030. Lam RW, Gorman CP, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995;152(12):1765-70.

1031. Ruhrmann S, Kasper S, Hawellek B, et al. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998;28(4):923-33.

1032. Lee TM, Chan CC. Dose-response relationship of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiatr Scand 1999;99(5):315-23.

1033. Lam RW, Levitt AJ. Canadian consensus guidelines for the treatment of seasonal affective disorder. Vancouver: Clinical Academic Publishing; 1999.

1034. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005;162(4):656-62.

1035. Eastman CI, Young MA, Fogg LF, et al. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 1998;55(10):883-9.

1036. Terman M, Terman JS, Ross DC. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 1998;55(10):875-82.

1037. Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev 2004;CD004050.

1038. World Health Organization (WHO). Global Recommendations on Physical Activity for Health. Geneva: 2010 [cited: 2016-09-14]. http://whqlibdoc.who.int/publications/2010/9789241599979_eng.pdf.

1039. American College of Sports Medicine (ACSM). ACSM’s resource manual for guidelines for exercise testing and prescription. Philadelphia: Lippincott Williams and Wilkins; 2001.

1040. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43(7):1334-59.

1041. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev 2013;CD004366.

1042. Krogh J, Nordentoft M, Sterne JA, et al. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2011;72(4):529-38.

1043. Pinchasov BB, Shurgaja AM, Grischin OV, et al. Mood and energy regulation in seasonal and non-seasonal depression before and after midday treatment with physical exercise or bright light. Psychiatry Res 2000;94(1):29-42.

1044. Robertson R, Robertson A, Jepson R, et al. Walking for depression or depressive symp-toms: a systematic reviewand meta-analysis. Mental Health and Physical Activity 2012;5:66–75.

1045. Blake H, Mo P, Malik S, et al. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil 2009;23(10):873-87.

1046. Bridle C, Spanjers K, Patel S, et al. Effect of exercise on depression severity in older people: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2012;201(3):180-5.

1047. Potter R, Ellard D, Rees K, et al. A systematic review of the effects of physical activity on physical functioning, quality of life and depression in older people with dementia. Int J Geriatr Psychiatry 2011;26(10):1000-11.

1048. Gellis ZD, Kang-Yi C. Meta-analysis of the effect of cardiac rehabilitation interventions on depression outcomes in adults 64 years of age and older. Am J Geriatr Cardiol 2012;110(9):1219-24.

1049. van het Hoofd MGV, Roelse H, Kwakkel G, et al. Does exercise therapy affect depression or depressive symptoms after stroke? Phys Ther Rev 2011;13(3):191-200.

1050. Craft LL, Vaniterson EH, Helenowski IB, et al. Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21(1):3-19.

1051. Brown JC, Huedo-Medina TB, Pescatello LS, et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. PLoS One 2012;7(1):e30955.

1052. Oh B, Choi SM, Inamori A, et al. Effects of qigong on depression: a systemic review. Evid Based Complement Alternat Med 2013;2013:134737.

1053. Wang C, Bannuru R, Ramel J, et al. Tai Chi on psychological well-being: systematic review and meta-analysis. BMC Complement Altern Med 2010;10:23.

1054. Wang F, Man JK, Lee EK, et al. The effects of qigong on anxiety, depression, and psychological well-being: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2013;2013:152738.

1055. Scottish Intercollegiate Guidelines Network (SIGN). Nonpharmaceutical management of depression in adults. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2010. http://www.sign.ac.uk/pdf/sign114.pdf.

1056. George MS, Lisanby SH, Sackheim HA. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry 1999;56(4):300-11.

1057. McNamara B, Ray JL, Arthurs OJ, et al. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 2001;31(7):1141-6.

1058. Pascual-Leone A, Rubio B, Pallardo F, et al. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996;348(9022):233-7.

1059. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998;108(1):1-16.

1060. Rossi S, Hallett M, Rossini PM, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009;120(12):2008-39.

1061. Wassermann EM. Side effects of repetitive transcranial magnetic stimulation. Depress Anxiety 2000;12(3):124-9.

1062. Lefaucheur JP, Andre-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125(11):2150-206.

1063. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62(11):1208-16.

1064. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67(5):507-16.

1065. Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 2015;14(1):64-73.

1066. Berlim MT, van den Eynde F, Tovar-Perdomo S, et al. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med 2014;44(2):225-39.

1067. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. J Affect Disord 2009;118(1-3):94-100.

1068. Herwig U, Fallgatter AJ, Hoppner J, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. Br J Psychiatry 2007;191:441-8.

1069. George MS, Sackeim HA, Rush AJ, et al. Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry 2000;47(4):287-95.

1070. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58(5):347-54.

1071. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005;58(5):355-63.

1072. Martin JL, Martin-Sanchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. Eur Psychiatry 2012;27(3):147-55.

1073. Schene AH, Koeter MW, Kikkert MJ, et al. Adjuvant occupational therapy for work-related major depression works: randomized trial including economic evaluation. Psychol Med 2007;37(3):351-62.

1074. Reuster T. Effektivität der Ergotherapie im psychiatrischen Krankenhaus. Mit einer Synopse zu Geschichte, Stand und aktueller Entwicklung der psychiatrischen Ergotherapie. Darmstadt: Steinkopff; 2006.

1075. Kramer B, Simon M, Katschnig H. Die Beurteilung psychiatrischer Berufsgruppen durch die Angehörigen. Psychiatr Prax 1996;23(1):29-32.

1076. Ziemann GH. Der Stellenwert der Ergotherapie im stationären psychiatrischen Therapiekonzept - Ergebnisse einer Befragung von Patienten und Angestellten. In: Reuster T, Bach O, editors. Ergotherapie und Psychiatrie. Perspektiven aktueller Forschung. Stuttgart: Thieme; 2002. p. 85-98.

1077. Brieger P, Marneros A. Komorbidität bei psychiatrischen Krankheiten. Nervenarzt 2000;71(7):525-34.

1078. Simon GE, Von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52(10):850-6.

1079. Verbosky LA, Franco KN, Zrull JP. The relationship between depression and length of stay in the general hospital patient. J Clin Psychiatry 1993;54(5):177-81.

1080. Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990;51(Suppl 6):3-11.

1081. Sharma V, Mazmanian D, Persad E, et al. A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Can J Psychiatry 1995;40(5):270-4.

1082. Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks. Development, diagnostic stability, and course of illness. Arch Gen Psychiatry 1986;43(11):1029-36.

1083. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl 1998;98(393):6-11.

1084. Kendall PC, Flannery-Schroeder EC. Methodological issues in treatment research for anxiety disorders in youth. J Abnorm Child Psychol 1998;26(1):27-38.

1085. Lecrubier Y. Is depression under-recognized and undertreated? Int Clin Psychopharmacol 1998;13(Suppl 5):S3-S6.

1086. Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992;60(6):835-44.

1087. Noyes J, Woodman C, Garvey MJ, et al. Generalized anxiety disorder vs. panic disorder. Distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 1992;180(6):369-79.

1088. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993;150(4):600-7.

1089. Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995;56(Suppl 6):22-9.

1090. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4 ed. Washington: American Psychiatric Association (APA); 1994.

1091. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 2004;10(5):296-306.

1092. Parker G, Wilhelm K, Mitchell P, et al. Predictors of 1-year outcome in depression. Aust N Z J Psychiatry 2000;34(1):56-64.

1093. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001;62(Suppl 11):37-42.

1094. Chambless DL, Gillis MM. Cognitive therapy of anxiety disorders. J Consult Clin Psychol 1993;61(2):248-60.

1095. Gould RA, Otto MW, Pollack MH, et al. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analyis. Behav Ther 1997;28(2):285-305.

1096. Borkovec TD, Whisman MA. Psychosocial treatment for generalized anxiety disorder. In: Mavissakalian MR, Prien RF, editors. Long-term treatments of anxiety disorders. Washington: American Psychiatric Publishing; 1996.

1097. Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. Jama 2000;283(19):2529-36.

1098. Soyka M, Lieb M. Komorbidität von Depression und Alkoholabhängigkeit: Klinische und neurobiologische Aspekte. Nervenheilkunde 2004;23:13-20.

1099. Ross HE, Swinson R, Larkin EJ, et al. Diagnosing comorbidity in substance abusers. Computer assessment and clinical validation. J Nerv Ment Dis 1994;182(10):556-63.

1100. Dongier M. What are the treatment options for comorbid alcohol abuse and depressive disorders? J Psychiatry Neurosci 2005;30(3):224.

1101. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54(8):700-5.

1102. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Jama 1996;275(10):761-7.

1103. Su-Jung Y, Chi-Un P, Dai-Jin K, et al. Mirtazapine für patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(7):1196-201.

1104. Brown RA, Ramsey SE. Addressing comorbid depressive symptomatology in alcohol treatment. Prof Psychol 2000;31(4):418-22.

1105. Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003;38(6):619-25.

1106. Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005;78(1):1-22.

1107. Nunes EV, Levin FR. Treatment of co-occurring depression and substance dependence: using meta-analysis to guide clinical recommendations. Psychiatr Ann 2008;38(11):730-8.

1108. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. Jama 2004;291(15):1887-96.

1109. Iovieno N, Tedeschini E, Bentley KH, et al. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2011;72(8):1144-51.

1110. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. AWMF-Register Nr. 076-001. 2015 [cited: 2016-09-14]. http://www.awmf.org/uploads/tx_szleitlinien/076-001l_S3-Leitlinie_Alkohol_2016-02.pdf.

1111. Piran N, Kennedy S, Garfinkel PE. Affective disturbance in eating disorders. J Nerv Ment Dis 1985;173(7):395-400.

1112. Strober M, Katz J. Depression in the eating disorder: a review and analysis of descriptive, family and biological factors. In: Garner DM, Garfinkel PE, editors. Diagnostic issues in anorexia nervosa and bulimia nervosa. New York: Brunner und Mazel; 1988. p. 80-111.

1113. Woodside BD, Staab R. Management of psychiatric comorbidity in anorexia nervosa and bulimia nervosa. CNS Drugs 2006;20(8):655-63.

1114. Kennedy SH, Kaplan AS, Garfinkel PE, et al. Depression in anorexia nervosa and bulimia nervosa: discriminating depressive symptoms and episodes. J Psychosom Res 1994;38(7):773-82.

1115. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49(2):139-47.

1116. Goldstein DJ, Wilson MG, Ascroft RC, et al. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord 1999;25(1):19-27.

1117. Rothschild R, Quitkin HM, Quitkin FM, et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int J Eat Disord 1994;15(1):1-9.

1118. Krüger S, Kennedy SH. Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder. J Psychiatry Neurosci 2000;25(5):497-508.

1119. Wold PN. Eating disorder symptoms in affective disorder. J Psychiatry Neurosci 1991;16(4):204-8.

1120. National Institute for Health and Clinical Excellence (NICE). Eating disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical Guideline 9. 2004 [cited: 2016-09-14]. http://www.nice.org.uk/guidance/CG9.

1121. Zimmerman M, Coryell W, Pfohl B, et al. ECT response in depressed patients with and without a DSM-III personality disorder. Am J Psychiatry 1986;143(8):1030-2.

1122. Shea MT, Hirschfeld RM. Chronic mood disorder and depressive personality. Psychiatr Clin North Am 1996;19(1):103-20.

1123. Shea MT, Pilkonis PA, Beckham E, et al. Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1990;147(6):711-8.

1124. Flick SN, Roy-Byrne PP, Cowley DS, et al. DSM-III-R personality disorders in a mood and anxiety disorders clinic: prevalence, comorbidity, and clinical correlates. J Affect Disord 1993;27(2):71-9.

1125. Corruble E, Ginestet D, Guelfi JD. Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord 1996;37(2-3):157-70.

1126. Brieger P, Ehrt U, Bloeink R, et al. Consequences of comorbid personality disorders in major depression. J Nerv Ment Dis 2002;190(5):304-9.

1127. Mulder RT. Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002;159(3):359-71.

1128. Casey P, Birbeck G, McDonagh C, et al. Personality disorder, depression and functioning: results from the ODIN study. J Affect Disord 2004;82(2):277-83.

1129. Mulder R. Personality disorder and outcome in depression. Br J Psychiatry 2006;189:186-7.

1130. Zimmerman M. Diagnosing personality disorders. A review of issues and research methods. Arch Gen Psychiatry 1994;51(3):225-45.

1131. Tyrer P. Somatoform and personality disorders: personality and the soma. J Psychosom Res 1995;39(4):395-7.

1132. Özmen M, Özmen E. Treatment approaches in patients with comorbid depression and personality disorder. Yeni Symposium: psikiyatri, nöroloji ve davranis bilimleri dergisi 2005;43(2):54-7.

1133. Pilkonis PA, Frank E. Personality pathology in recurrent depression: nature, prevalence, and relationship to treatment response. Am J Psychiatry 1988;145(4):435-41.

1134. Hardy GE, Barkham M, Shapiro DA, et al. Impact of Cluster C personality disorders on outcomes of contrasting brief psychotherapies for depression. J Consult Clin Psychol 1995;63(6):997-1004.

1135. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006;188(1):13-20.

1136. Ezquiaga E, Garcia A, Bravo F, et al. Factors associated with outcome in major depression: a 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol 1998;33(11):552-7.

1137. O'Leary D, Costello F. Personality and outcome in depression: an 18-month prospective follow-up study. J Affect Disord 2001;63(1-3):67-78.

1138. Peselow ED, Fieve RR, DiFiglia C. Personality traits and response to desipramine. J Affect Disord 1992;24(4):209-16.

1139. Sato T, Sakado K, Sato S, et al. Cluster a personality disorder: a marker of worse treatment outcome of major depression? Psychiatry Res 1994;53(2):153-9.

1140. Casey P, Meagher D, Butler E. Personality, functioning, and recovery from major depression. J Nerv Ment Dis 1996;184(4):240-5.

1141. Sareen J, Enns MW, Guertin JE. The impact of clinically diagnosed personality disorders on acute and one-year outcomes of electroconvulsive therapy. J ECT 2000;16(1):43-51.

1142. Duggan CF, Lee AS, Murray RM. Does personality predict long-term outcome in depression? Br J Psychiatry 1990;157:19-24.

1143. Russell JM, Kornstein SG, Shea MT, et al. Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. J Clin Psychiatry 2003;64(5):554-61.

1144. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989;13(6):885-93.

1145. Cornelius JR, Soloff PH, Perel JM, et al. Fluoxetine trial in borderline personality disorder. Psychopharmacology bulletin 1990;26(1):151-4.

1146. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50(5):377-85.

1147. Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacology bulletin 1989;25(4):524-34.

1148. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45(2):111-9.

1149. Lieb K, Vollm B, Rucker G, et al. Pharmacotherapy for borderline personality disorder: cochrane systematic review of randomised trials. Br J Psychiatry 2010;196(1):4-12.

1150. Stuart S, Simons AD, Thase ME, et al. Are personality assessments valid in acute major depression? J Affect Disord 1992;24(4):281-9.

1151. Diguer L, Barber JP, Luborsky L. Three concomitants: personality disorders, psychiatric severity, and outcome of dynamic psychotherapy of major depression. Am J Psychiatry 1993;150(8):1246-8.

1152. Hoffart A, Martinsen EW. Coping strategies in major depressed, agoraphobic and comorbid in-patients: a longitudinal study. Br J Med Psychol 1993;66(2):143-55.

1153. Hoffart A, Martinsen EW. The effects of personality disorders and anxious-depressive comorbidity in patients with unipolar depression and with panic disorder and agoraphobia. J Pers Disord 1993;7(4):304-11.

1154. Kool S, Dekker J, Duijsens IJ, et al. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry 2003;11(3):133-41.

1155. Bellino S, Zizza M, Rinaldi C, et al. Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Can J Psychiatry 2006;51(7):453-60.

1156. Rief W, Schaefer S, Hiller W, et al. Lifetime diagnoses in patients with somatoform disorders: which came first? Eur Arch Psychiatry Clin Neurosci 1992;241(4):236-40.

1157. Hiller W, Rief W, Fichter MM. How disabled are patients with somatoform disorders? Gen Hosp Psychiatry 1997;19(6):432-8.

1158. Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM). S3-Leitlinie Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden. AWMF-Register Nr. 051-001. 2012. http://www.awmf.org/uploads/tx_szleitlinien/051-001l_S3_Nicht-spezifische_funktionelle_somatoforme_Koerperbeschwerden_2012-04.pdf.

1159. Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 2001;63(1):35-41.

1160. Wells KB, Golding JM, Burnam MA. Psychiatric disorder and limitations in physical functioning in a sample of the Los Angeles general population. Am J Psychiatry 1988;145(6):712-7.

1161. Härter M, Bengel J. Epidemiologie psychischer Störungen in der medizinischen Rehabilitation (Unveröffentlichter Projektbericht). Freiburg: Universität Freiburg, Institut für Psychologie; 2001.

1162. Jacobi F. Psychische Störungen bei Patienten mit körperlichen Erkrankungen in der Allgemeinbevölkerung. In: Härter M, Baumeister H, Bengel J, editors. Psychische Störungen bei körperlichen Erkrankungen. Berlin: Springer; 2007. p. 45-53.

1163. Härter M, Baumeister H. Ätiologie psychischer Störungen bei chronischen körperlichen Erkrankungen. Berlin: Springer; 2007.

1164. Herrmann-Lingen C, Buss U. Angst und Depressivität im Verlauf der koronaren Herzkrankheit. Frankfurt: VAS; 2002.

1165. Taylor D, Meader N, Bird V, et al. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. Br J Psychiatry 2011;198(3):179-88.

1166. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005;58(3):175-89.

1167. Beltman MW, Voshaar RCO, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Br J Psychiatry 2010;197(1):11-9.

1168. Rizzo M, Creed F, Goldberg D, et al. A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems. J Psychosom Res 2011;71(1):18-27.

1169. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21(1):30-8.

1170. Tully PJ, Baune BT. Comorbid anxiety disorders alter the association between cardiovascular diseases and depression: the German National Health Interview and Examination Survey. Soc Psychiatry Psychiatr Epidemiol 2014;49(5):683-91.

1171. Rugulies R, Siegrist J. Soziologische Aspekte der Entstehung und des Verlaufs der koronaren Herzkrankheit: Soziale Ungleichverteilung der Erkrankung und chronische Distress-Erfahrungen. Frankfurt/Main: VAS; 2002.

1172. Baumeister H, Hutter N. Koronare Herzerkrankung und psychische Störungen. In: Berufsverband Deutscher Psychologinnen und Psychologen (BDP), editor. Die großen Volkskrankheiten - Beiträge der Psychologie zu Prävention, Gesundheitsförderung und Behandlung. Berlin: Berufsverband Deutscher Psychologinnen und Psychologen (BDP); 2012. p. 55-65.

1173. Hutter N, Baumeister H, Bengel J. Koronare Herzerkrankung und Depression. Zusammenhang, Diagnostik und Therapie. Internist Prax 2009;49:813-20.

1174. Faller H. Depression: Ein prognostischer Faktor bei koronarer Herzkrankheit. Psychotherapeut 2005;50:265-73.

1175. Albus C, Köhle K. Krankheitsverarbeitung und Psychotherapie nach Herzinfarkt. In: Uexküll TV, editor. Psychosomatische Medizin: Modelle ärztlichen Denkens und Handelns. München: Urban und Fischer; 2003. p. 879-89.

1176. Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002;26(8):941-62.

1177. Hesslinger B, Härter M, Barth J, et al. Komorbidität von depressiven Störungen und kardiovaskularen Erkrankungen. Implikationen fur Diagnostik, Pharmako- und Psychotherapie. Nervenarzt 2002;73(3):205-17.

1178. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011;(9):CD008012.

1179. Glassman AH, Rodriguez AI, Shapiro PA. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry 1998;59:16-21.

1180. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321(6):406-12.

1181. Dwight MM, Stoudemire A. Effects of depressive disorders on coronary artery disease: a review. Harv Rev Psychiatry 1997;5(3):115-22.

1182. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000;108(1):2-8.

1183. Zuidersma M, Conradi HJ, van Melle JP, et al. Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res 2013;74(1):25-30.

1184. Lundbeck GmbH. Rote-Hand-Brief vom 31.10.2011 zu Cipramil® (Citalopram): Zusammenhang von Cipramil® (Citalopramhydrobromid/Citalopramhydrochlorid) mit dosisabhängiger QT-Intervall-Verlängerung. 2011 [cited: 2016-09-14]. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2011/20111031.pdf.

1185. Lundbeck GmbH. Rote-Hand-Brief vom 05.12.2011 zu Escitalopram (Cipralex®): Zusammenhang von Escitalopram (Cipralex®) mit dosisabhängiger QT-Intervall-Verlängerung. 2011 [cited: 2016-09-14]. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2011/20111205.pdf.

1186. Shin D, Oh YH, Eom CS, et al. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol 2014;261(4):686-95.

1187. Rieckmann N, Kronish IM, Shapiro PA, et al. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Intern Med 2013;173(12):1150-1.

1188. Huang CJ, Hsieh MH, Hou WH, et al. Depression, antidepressants, and the risk of coronary heart disease: a population-based cohort study. Int J Cardiol 2013;168(5):4711-6.

1189. Dekker RL. Cognitive therapy for depression in patients with heart failure: a critical review. Heart Fail Clin 2011;7(1):127-41.

1190. Dickens C, Cherrington A, Adeyemi I, et al. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med 2013;75(2):211-21.

1191. ENRICHD I. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. Am Heart J 2000;139(1 Pt 1):1-9.

1192. ENRICHD I. Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. Psychosom Med 2001;63(5):747-55.

1193. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. Jama 2003;289(23):3106-16.

1194. Hill DR, Kelleher K, Shumaker SA. Psychosocial interventions in adult patients with coronary heart disease and cancer. A literature review. Gen Hosp Psychiatry 1992;14(6 Suppl):28S-42S.

1195. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. Bmj 1996;313(7071):1517-21.

1196. Mullen PD, Mains DA, Velez R. A meta-analysis of controlled trials of cardiac patient education. Patient Educ Couns 1992;19(2):143-62.

1197. Thompson DR, Lewin RJ. Coronary disease. Management of the post-myocardial infarction patient: rehabilitation and cardiac neurosis. Heart 2000;84(1):101-5.

1198. Carney RM, Freedland KE, Stein PK, et al. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med 2000;62(5):639-47.

1199. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007;190:460-6.

1200. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. Diabet Med 2014;31(7):773-86.

1201. Frasure-Smith N, Lesperance F. Depression and other psychological risks following myocardial infarction. Arch Gen Psychiatry 2003;60(6):627-36.

1202. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke 2014;9(8):1017-25.

1203. Kronenberg G, Katchanov J, Endres M. Poststroke-Depression: Klinik, Epidemiologie, Therapie, pathophysiologische Konzepte. Nervenarzt 2006;77(10):1176-85.

1204. Ihle-Hansen H, Thommessen B, Fagerland MW, et al. Effect on anxiety and depression of a multifactorial risk factor intervention program after stroke and TIA: a randomized controlled trial. Aging Ment Health 2014;18(5):540-6.

1205. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36(5):1098-103.

1206. Tharwani HM, Yerramsetty P, Mannelli P, et al. Recent advances in poststroke depression. Curr Psychiatry Rep 2007;9(3):225-31.

1207. Iovieno N, Tedeschini E, Ameral VE, et al. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol 2011;26(2):69-74.

1208. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008;CD003437.

1209. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Schlaganfall. DEGAM-Leitlinie Nr. 8. Frankfurt a. M.: 2012 [cited: 2016-09-14]. http://www.degam.de/degam-leitlinien-379.html.

1210. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. Int J Clin Pract 2010;64(9):1310-7.

1211. Chen Y, Patel NC, Guo JJ, et al. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol 2007;22(3):159-66.

1212. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. Jama 2008;299(20):2391-400.

1213. Bhogal SK, Teasell R, Foley N, et al. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. J Am Geriatr Soc 2005;53(6):1051-7.

1214. Currier MB, Murray GB, Welch CC. Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 1992;4(2):140-4.

1215. Murray GB, Shea V, Conn DK. Electroconvulsive therapy for poststroke depression. J Clin Psychiatry 1986;47(5):258-60.

1216. Gordon WA, Hibbard MR. Poststroke depression: an examination of the literature. Arch Phys Med Rehabil 1997;78(6):658-63.

1217. Kneebone II, Dunmore E. Psychological management of post-stroke depression. Br J Clin Psychol 2000;39(Pt 1):53-65.

1218. Roth AJ, McClear KZ, Massie MJ. Oncology. In: Stoudemire A, Fogel B, Greenberg D, editors. Psychiatric care of the medical patient. 2 ed. New York: Oxford University Press; 2000. p. 733-55.

1219. Musselman DL, Somerset WI, Guo Y, et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 2006;67(2):288-96.

1220. Shuster JL, Chochinov HM, Greenberg DB. Psychiatric aspects and psychopharmacologic strategies in palliative care. In: Stoudemire A, Fogel B, Greenberg D, editors. Psychiatric care of the medical patient. 2 ed. New York: Oxford University Press; 2000. p. 315-27.

1221. Laoutidis ZG, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry 2013;13:140.

1222. Cankurtaran ES, Ozalp E, Soygur H, et al. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 2008;16(11):1291-8.

1223. Lydiatt WM, Bessette D, Schmid KK, et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol Head Neck Surg 2013;139(7):678-86.

1224. Antoni MH, Lehman JM, Kilbourn KM, et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychol 2001;20(1):20-32.

1225. Giese-Davis J, Koopman C, Butler LD, et al. Change in emotion-regulation strategy for women with metastatic breast cancer following supportive-expressive group therapy. J Consult Clin Psychol 2002;70(4):916-25.

1226. Hopko DR, Armento ME, Robertson SM, et al. Brief behavioral activation and problem-solving therapy for depressed breast cancer patients: randomized trial. J Consult Clin Psychol 2011;79(6):834-49.

1227. Piet J, Wurtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. J Consult Clin Psychol 2012;80(6):1007-20.

1228. Luckett T, Britton B, Clover K, et al. Evidence for interventions to improve psychological outcomes in people with head and neck cancer: a systematic review of the literature. Support Care Cancer 2011;19(7):871-81.

1229. Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 2013;31(6):782-93.

1230. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA. S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.0. AWMF-Register Nr. 032/051OL. 2014 [cited: 2016-09-14]. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html.

1231. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24(6):1069-78.

1232. Rotella F, Mannucci E. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry 2013;74(1):31-7.

1233. Rubin RR, Ciechanowski P, Egede LE, et al. Recognizing and treating depression in patients with diabetes. Curr Diab Rep 2004;4(2):119-25.

1234. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59(3):241-50.

1235. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63(4):619-30.

1236. Lustman PJ, Freedland KE, Griffith LS, et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000;23(5):618-23.

1237. Pan A, Lucas M, Sun Q, et al. Increased mortality risk in women with depression and diabetes mellitus. Arch Gen Psychiatry 2011;68(1):42-50.

1238. Scherrer JF, Garfield LD, Chrusciel T, et al. Increased risk of myocardial infarction in depressed patients with type 2 diabetes. Diabetes Care 2011;34(8):1729-34.

1239. van Dooren FE, Nefs G, Schram MT, et al. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013;8(3):e57058.

1240. Black SA. Increased health burden associated with comorbid depression in older diabetic Mexican Americans. Results from the Hispanic Established Population for the Epidemiologic Study of the Elderly survey. Diabetes Care 1999;22(1):56-64.

1241. Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care 2003;26(10):2822-8.

1242. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25(3):464-70.

1243. Egede LE. Diabetes, major depression, and functional disability among U.S. adults. Diabetes Care 2004;27(2):421-8.

1244. Hermanns N, Kulzer B, Krichbaum M, et al. Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors. Diabet Med 2005;22(3):293-300.

1245. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care 1997;20(4):585-90.

1246. Egede LE, Zheng D. Independent factors associated with major depressive disorder in a national sample of individuals with diabetes. Diabetes Care 2003;26(1):104-11.

1247. Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008;31(12):2383-90.

1248. Lustman PJ, Griffith LS, Clouse RE. Depression in Adults with Diabetes. Semin Clin Neuropsychiatry 1997;2(1):15-23.

1249. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-62.

1250. Kubiak T, Weik A, Kulzer B. Behandlung psychischer Störungen bei diabetes mellitus. In: Härter M, editor. Psychische Störungen bei körperlichen Erkrankungen. Berlin: Springer; 2007. p. 111-24.

1251. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004;164(13):1395-404.

1252. Goodnick PJ, Kumar A, Henry JH, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacology bulletin 1997;33(2):261-4.

1253. Markowitz SM, Gonzalez JS, Wilkinson JL, et al. A review of treating depression in diabetes: emerging findings. Psychosomatics 2011;52(1):1-18.

1254. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006;63(5):521-9.

1255. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163(20):2433-45.

1256. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006;68(2):262-8.

1257. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60(1):39-47.

1258. Chaichana KL, Mukherjee D, Adogwa O, et al. Correlation of preoperative depression and somatic perception scales with postoperative disability and quality of life after lumbar discectomy. J Neurosurg Spine 2011;14(2):261-7.

1259. Fishbain DA, Cutler R, Rosomoff HL, et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997;13(2):116-37.

1260. Fishbain DA, Cutler R, Rosomoff HL, et al. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000;1(4):310-6.

1261. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26(1):30-6.

1262. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005;CD005454.

1263. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. Bmj 2007;335(7610):87.

1264. Keefe FJ. Can cognitive-behavioral therapies succeed where medical treatments fail? In: Devor M, Rowbotham MC, Wiesenfeld-Hallin Z, editors. Proceedings of the 9'th World Congress on Pain: progress in pain research and management. Seattle: IASP; 2000. p. 1069–1084.

1265. Karp JF, Weiner D, Seligman K, et al. Body pain and treatment response in late-life depression. Am J Geriatr Psychiatry 2005;13(3):188-94.

1266. Dixon KE, Keefe FJ, Scipio CD, et al. Psychological interventions for arthritis pain management in adults: a meta-analysis. Health Psychol 2007;26(3):241-50.

1267. Hoffman BM, Papas RK, Chatkoff DK, et al. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol 2007;26(1):1-9.

1268. Glombiewski JA, Hartwich-Tersek J, Rief W. Depression in chronic back pain patients: prediction of pain intensity and pain disability in cognitive-behavioral treatment. Psychosomatics 2010;51(2):130-6.

1269. Kroenke K, Bair M, Damush T, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain. A randomized controlled trial. Jama 2009;301(20):2099-110.

1270. Lin EHB, Katon W, Von Korff M, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. Jama 2003;290(18):2428-34.

1271. Parker J, Smarr K, Slaughter J, et al. Management of depression in rheumatoid arthritis: a combined and pharmacologic and cognitive-behavioral approach. Arthritis Rheum 2003;49(6):766-77.

1272. Zautra AJ, Davis MC, Reich JW, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol 2008;76(3):408-21.

1273. Scheidt CE, Waller E, Endorf K, et al. Is brief psychodynamic psychotherapy in primary fibromyalgia syndrome with concurrent depression an effective treatment? A randomized controlled trial. Gen Hosp Psychiatry 2013;35(2):160-7.

1274. Lyketsos CG, Steele C, Baker L, et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9(4):556-61.

1275. Migliorelli R, Teson A, Sabe L, et al. Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease. Am J Psychiatry 1995;152(1):37-44.

1276. Stoppe G, Staedt J. Die frühe diagnostische Differenzierung primär dementer von primär depressiven Syndromen im Alter - ein Beitrag zur Pseudodemenzdiskussion. Fortschr Neurol Psychiatr 1993;61(5):172-82.

1277. Gao Y, Huang C, Zhao K, et al. Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Int J Geriatr Psychiatry 2013;28(5):441-9.

1278. Luppa M, Luck T, Ritschel F, et al. Depression and incident dementia. An 8-year population-based prospective study. PLoS One 2013;8(3):e59246.

1279. Vinkers DJ, Gussekloo J, Stek ML, et al. Temporal relation between depression and cognitive impairment in old age: prospective population based study. Bmj 2004;329(7471):881.

1280. Heser K, Tebarth F, Wiese B, et al. Age of major depression onset, depressive symptoms, and risk for subsequent dementia: results of the German study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe). Psychol Med 2013;43(8):1597-610.

1281. Castilla-Puentes RC, Habeych ME. Subtypes of depression among patients with Alzheimer's disease and other dementias. Alzheimers Dement 2010;6(1):63-9.

1282. Visser PJ, Verhey FR, Scheltens P, et al. Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. J Neurol 2002;249(3):312-9.

1283. Lim WS, Rubin EH, Coats M, et al. Early-stage Alzheimer disease represents increased suicidal risk in relation to later stages. Alzheimer Dis Assoc Disord 2005;19(4):214-9.

1284. Richard E, Reitz C, Honig LH, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013;70(3):374-82.

1285. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17(1-2):100-8.

1286. Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am 2002;86(3):657-74.

1287. Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61(7):487-92.

1288. Cowen PJ. Advances in psychopharmacology: mood disorders and dementia. Br Med Bull 1996;52(3):539-55.

1289. Teri L, Logsdon RG, Uomoto J, et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci 1997;52(4):159-66.

1290. Gallassi R, di Sarro R, Morreale A, et al. Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord 2006;91(2-3):243-50.

1291. Bains J, Birks JS, Dening TR. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev 2002;CD003944.

1292. Munro CA, Brandt J, Sheppard JM, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 2004;12(5):491-8.

1293. Munro CA, Longmire CF, Drye LT, et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry 2012;20(12):1036-44.

1294. Koenig AM, Butters MA, Begley A, et al. Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning. J Clin Psychiatry 2014;75(2).

1295. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Jama 2002;288(12):1475-83.

1296. Petracca G, Teson A, Chemerinski E, et al. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8(3):270-5.

1297. Shabnam GN, th C, Kho D, et al. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003;CD003465.

1298. Skapinakis P, Bakola E, Salanti G, et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 2010;10:49.

1299. Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm 2014;29(4):254-63.

1300. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen 2011;26(3):169-83.

1301. Price TR, McAllister TW. Safety and efficacy of ECT in depressed patients with dementia: a review of clinical experience. Convuls Ther 1989;5(1):61-74.

1302. Rao V, Lyketsos CG. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry 2000;15(8):729-35.

1303. Hausner L, Damian M, Sartorius A, et al. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J Clin Psychiatry 2011;72(1):91-7.

1304. Cusin C, Franco FB, Fernandez-Robles C, et al. Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. Gen Hosp Psychiatry 2013;35(6):29.

1305. Takahashi S, Mizukami K, Yasuno F, et al. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics 2009;9(2):56-61.

1306. Oudman E. Is electroconvulsive therapy (ECT) effective and safe for treatment of depression in dementia? A short review. J ECT 2012;28(1):34-8.

1307. Liu AY, Rajji TK, Blumberger DM, et al. Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression. Am J Geriatr Psychiatry 2014;22(3):216-40.

1308. Orgeta V, Qazi A, Spector AE, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev 2014;CD009125.

1309. Waldorff FB, Buss DV, Eckermann A, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). Bmj 2012;345:e4693.

1310. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23(2):183-9.

1311. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886-92.

1312. Xie CL, Wang XD, Chen J, et al. A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson's disease patients. Neurol Sci 2015;36(6):833-43.

1313. Alarcon RD. Culture, cultural factors and psychiatric diagnosis: review and projections. World Psychiatry 2009;8(3):131-9.

1314. Bhugra D. Severe mental illness across cultures. Acta Psychiatr Scand Suppl 2006;429(Suppl 429):17-23.

1315. Bhugra D, Mastrogianni A. Globalisation and mental disorders. Overview with relation to depression. Br J Psychiatry 2004;184(1):10-20.

1316. Glaesmer H, Wittig U, Brähler E, et al. Sind Migranten häufiger von psychischen Störungen betroffen? Eine Untersuchung an einer repräsentativen Stichprobe der deutschen Allgemeinbevölkerung. Psychiatr Prax 2009;36:16-22.

1317. Bermejo I, Muthny FA. Fazit und Empfehlungen für das Gesundheitssystem einer multikulturellen Gesellschaft. Köln: Deutscher Ärzte-Verlag; 2009.

1318. Wimmer-Puchinger B, Wolf H, Engleder A. Migrantinnen im Gesundheitssystem. Inanspruchnahme, Zugangsbarrieren und Strategien zur Gesundheitsförderung. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2006;49(9):884–92.

1319. Statistisches B. Bevölkerung und Erwerbstätigkeit: Bevölkerung mit Migrationshintergrund - Ergebnisse des Mikrozensus 2013. 2013 [cited: 2016-09-14]. http://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/MigrationIntegration/Migrationshintergrund2010220137004.pdf?__blob=publicationFile.

1320. Swinnen SG, Selten JP. Mood disorders and migration: meta-analysis. Br J Psychiatry 2007;190(1):6-10.

1321. Assion HJ. Migration und psychische Krankheit. Berlin, Heidelberg: Springer-Verlag; 2005.

1322. Kirmayer LJ, Weinfeld M, Burgos G, et al. Use of health care services for psychological distress by immigrants in an urban multicultural milieu. Can J Psychiatry 2007;52(5):295-304.

1323. Cabassa LJ, Zayas LH. Latino immigrants' intentions to seek depression care. Am J Orthopsychiatry 2007;77(2):231-42.

1324. Brzoska P, Voigtlander S, Spallek J, et al. Utilization and effectiveness of medical rehabilitation in foreign nationals residing in Germany. Eur J Epidemiol 2010;25(9):651-60.

1325. Igel U, Brähler E, Grande G. Der Einfluss von Diskriminierungserfahrungen auf die Gesundheit von Migranten. Psychiatr Prax 2010;37(4):183–90.

1326. Brucks U, Wahl WB. Über-, Unter-, Fehlversorgung? Bedarfslücken und Strukturprobleme in der ambulanten Gesundheitsversorgung für Migrantinnen und Migranten. Frankfurt: Mabuse; 2003.

1327. Bermejo I, Hölzel LP, Kriston l, et al. Subjektiv erlebte Barrieren von Personen mit Migrationshintergrund bei der Inanspruchnahme von Gesundheitsmaßnahmen. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012;55(8):944-53.

1328. Bermejo I, Kriston L, Berger M, et al. Patients’ language proficiency affects process and outcome quality of inpatient depression treatment in Germany. Psychiatr Serv 2009;60:545-8.

1329. Lindert J, Priebe S, Penka S, et al. Versorgung psychischkranker Patienten mit Migrationshintergrund. Psychother Psychosom Med 2008;58(3-4):123-9.

1330. Schouler-Ocak M, Rapp MA, Reiske SL, et al. Psychotherapie bei traumatisierten Patientinnen mit türkischem Migrationshintergrund: Berücksichtigung kultureller Faktoren. Psychother Psychosom Med 2008;58(3-4):169-75.

1331. Schraufnagel TJ, Wagner AW, Miranda J, et al. Treating minority patients with depression and anxiety: what does the evidence tell us? Gen Hosp Psychiatry 2006;28(1):27-36.

1332. Stompe T, Ortwein-Swoboda G, Chaudhry HR, et al. Guilt and depression: a cross-cultural comparative study. Psychopathology 2001;34(6):289-98.

1333. Wittkowski A, Gardner PL, Bunton P, et al. Culturally determined risk factors for postnatal depression in Sub-Saharan Africa: a mixed method systematic review. J Affect Disord 2014;163:115-24.

1334. Lewis-Fernandez R, Diaz N. The cultural formulation: a method for assessing cultural factors affecting the clinical encounter. Psychiatr Q 2002;73(4):271-95.

1335. Nika E, Basdekis R. Somatisierung. In: Haasen C, Yagdiran O, editors. Beurteilung psychischer Störungen in einer multikulturellen Gesellschaft. Freiburg im Breisgau: Lambertus; 2000.

1336. Levecque K, Lodewyckx I, Bracke P. Psychological distress, depression and generalised anxiety in Turkish and Moroccan immigrants in Belgium: a general population study. Soc Psychiatry Psychiatr Epidemiol 2009;44(3):188-97.

1337. Lindert J, Ehrenstein OS, Priebe S, et al. Depression and anxiety in labor migrants and refugees - a systematic review and meta-analysis. Soc Sci Med 2009;69(2):246-57.

1338. Erim Y. Klinische Interkulturelle Psychotherapie: Ein Lehr- und Praxisbuch. Stuttgart: Kohlhammer; 2009.

1339. Kirmayer LJ, Young A. Culture and somatization: clinical, epidemiological, and ethnographic perspectives. Psychosom Med 1998;60(4):420-30.

1340. Haasen C, Yagdiran O. Beurteilung psychischer Störungen in einer multikulturellen Gesellschaft. Freiburg: 2000.

1341. Karasz A. Cultural differences in conceptual models of depression. Soc Sci Med 2005;60(7):1625-35.

1342. Lawrence V, Murray J, Banerjee S, et al. Concepts and causation of depression: a cross-cultural study of the beliefs of older adults. Gerontologist 2006;46(1):23-32.

1343. Bermejo I, Mayninger E, Kriston L, et al. Psychische Störungen bei Menschen mit Migrationshintergrund im Vergleich zur deutschen Allgemeinbevölkerung. Psychiatr Prax 2010;37(05):225-32.

1344. Tarricone I, Atti AR, Salvatori F, et al. Psychotic symptoms and general health in a socially disadvantaged migrant community in Bologna. Int J Soc Psychiatry 2009;55(3):203-13.

1345. Rao D, Young M, Raguram R. Culture, somatization, and psychological distress: symptom presentation in South Indian patients from a public psychiatric hospital. Psychopathology 2007;40(5):349-55.

1346. Halbreich U, Alarcon RD, Calil H, et al. Culturally-sensitive complaints of depressions and anxieties in women. J Affect Disord 2007;102(1-3):159-76.

1347. Smits CH, de Vries WM, Beekman AT. The CIDI as an instrument for diagnosing depression in older Turkish and Moroccan labour migrants: an exploratory study into equivalence. Int J Geriatr Psychiatry 2005;20(5):436-45.

1348. World Health Organization (WHO). Depressive disorders in different cultures. Geneva: World Health Organization; 1983.

1349. Lay B, Lauber C, Rossler W. Are immigrants at a disadvantage in psychiatric in-patient care? Acta Psychiatr Scand 2005;111(5):358-66.

1350. Zeeb H, Razum O. Epidemiologische Studien in der Migrationsforschung: Ein einleitender Überblick. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2006;49(9):845-52.

1351. Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J Clin Psychiatry 2007;68(Suppl 2):36-41.

1352. van der Wurff FB, Beekman AT, Dijkshoorn H, et al. Prevalence and risk-factors for depression in elderly Turkish and Moroccan migrants in the Netherlands. J Affect Disord 2004;83(1):33-41.

1353. Koch E. Arzt-Patient-Beziehung und Transkulturelle Psychiatrie. Sozialpsychiatrische Informationen 2011;41:26–9.

1354. Gün AK. Interkulturelle Missverständnisse in der Psychotherapie - Gegenseitiges Verstehen zwischeneinheimischen Therapeuten und türkeistämmigen Klienten. Freiburg: Lambertus Verlag; 2007.

1355. Maoz B, Rabin S, Katz H, et al. Der zwischenmenschliche Ansatz in der Medizin: Die Arzt-Patienten-Beziehung. Berlin: Logos; 2006.

1356. Mösko M, Gil-Martinez F, Schulz H. Are migrants treated adequately? Outpatient psychotherapeutic public health care situation for people with migration background in a German metropolis. In: 39th International meeting of the Society for Psychotherapy Research. Barcelona: 2008.

1357. Fisek GO. Cultural context. Migration and health risks - A multilevel analysis. Osnabrück: Universitätsverlag Rasch; 2001.

1358. Kastrup M. Staff competence in dealing with traditional approaches. Eur Psychiatry 2008;23(Suppl 1):59-68.

1359. Okasha A. The impact of Arab culture on psychiatric ethics. In: Okasha A, Arboleda-Florez J, Sartorius N, editors. Ethics, culture and psychiatry: international perspectives. Washington: American Psychiatric Press; 2000. p. 9–28.

1360. Ghods BK, Roter DL, Ford DE, et al. Patient-physician communication in the primary care visits of African Americans and whites with depression. J Gen Intern Med 2008;23(5):600-6.

1361. Cooper LA, Roter DL, Johnson RL, et al. Patient-centered communication, ratings of care, and concordance of patient and physician race. Ann Intern Med 2003;139(11):907-15.

1362. Zeiler J. Psychiatrische Diagnostik bei Migranten: Typische Fehlerquellen. T & E Neurologie und Psychiatrie 1997;11:889–91.

1363. Behrens K, Calliess IT. Migration und Kultur als Determinanten diagnostischer und therapeutischer Prozesse bei seelisch erkrankten Migranten. Psychother Psychosom Med 2008;58(3-4):162-8.

1364. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care 2003;41(4):479-89.

1365. Cooper LA, Ghods Dinoso BK, Ford DE, et al. Comparative effectiveness of standard versus patient-centered collaborative care interventions for depression among African Americans in primary care settings: the BRIDGE Study. Health Serv Res 2013;48(1):150-74.

1366. Givens JL, Houston TK, Van Voorhees BW, et al. Ethnicity and preferences for depression treatment. Gen Hosp Psychiatry 2007;29(3):182-91.

1367. Walpole SC, McMillan D, House A, et al. Interventions for treating depression in Muslim Patients: a systematic review. J Affect Disord 2013;145(1):11-20.

1368. Garcia E, Franks P, Jerant A, et al. Depression treatment preferences of Hispanic individuals: exploring the influence of ethnicity, language and explanatory models. J Am Board Fam Med 2011;24(1):39–50.

1369. Dwight-Johnson M, Sherbourne CD, Liao D, et al. Treatment preferences among depressed primary care patients. J Gen Intern Med 2000;15(8):527-34.

1370. Lesser IM, Castro DB, Gaynes BN, et al. Ethnicity/race and outcome in the treatment of depression: results from STAR*D. Med Care 2007;45(11):1043-51.

1371. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008;84(3):347-61.

1372. Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001;11(6):489-99.

1373. Luo HR, Poland RE, Lin KM, et al. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006;80(1):33-40.

1374. Fuentes D, Aranda MP. Depression interventions among racial and ethnic minority older adults: a systematic review across 20 years. Am J Geriatr Psychiatry 2012;20(11):915-31.

1375. van Loon A, van Schaik A, Dekker J, et al. Bridging the gap for ethnic minority adult outpatients with depression and anxiety disorders by culturally adapted treatments. J Affect Disord 2013;147(1-3):9-16.

1376. Nickel C, Lojewski N, Muehlbacher N, et al. Behandlungsergebnisse stationärer psychosomatischer Rehabilitation bei türkischen Migranten: Eine prospektive Studie. Gesundheitswesen 2006;68(3):147-53.

1377. Behrens K, Calliess IT. Gleichbehandlung ohne gleiche Behandlung: Zur Notwendigkeit der Modifikationtherapeutischer Strategien für die Arbeit mit Migranten. Fortschr Neurol Psychiatr 2008;76(12):725-33.

1378. Sieberer M, Ziegenbein M, Clark D, et al. Gesundheit und Akkulturation durch Bewegung? Ergebnisse einer Querschnittsstudie zur körperlichen Aktivität von Migranten. Z Med Psychol 2009;18 (Sonderheft Migration und Gesundheit):170–9.

1379. O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol 2013;9:379-407.

1380. Essali A, Alabed S, Guul A, et al. Preventive interventions for postnatal psychosis. Cochrane Database Syst Rev 2013;CD009991.

1381. Dennis CL, Dowswell T. Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. Cochrane Database Syst Rev 2013;CD006795.

1382. Lancaster CA, Gold KJ, Flynn HA, et al. Risk factors for depressive symptoms during pregnancy: a systematic review. Am J Obstet Gynecol 2010;202(1):5-14.

1383. Uher R, Payne JL, Pavlova B, et al. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety 2014;31(6):459-71.

1384. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31(5):403-13.

1385. Meltzer-Brody S, Boschloo L, Jones I, et al. The EPDS-Lifetime: assessment of lifetime prevalence and risk factors for perinatal depression in a large cohort of depressed women. Arch Womens Ment Health 2013;16(6):465-73.

1386. Paulson JF, Bazemore SD. Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. Jama 2010;303(19):1961-9.

1387. Ramchandani PG, Stein A, O'Connor TG, et al. Depression in men in the postnatal period and later child psychopathology: a population cohort study. J Am Acad Child Adolesc Psychiatry 2008;47(4):390-8.

1388. National Collaborating Centre for Mental Health. Antenatal and postnatal mental health. Clinical management and service guidance. Draft version (July 2014). 2014.

1389. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150(6):782-6.

1390. Thombs BD, Arthurs E, Coronado-Montoya S, et al. Depression screening and patient outcomes in pregnancy or postpartum: a systematic review. J Psychosom Res 2014;76(6):433-46.

1391. Austin MP, Priest SR, Sullivan EA. Antenatal psychosocial assessment for reducing perinatal mental health morbidity. Cochrane Database Syst Rev 2008;CD005124.

1392. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013;74(4):e321-e341.

1393. Pariante CM, Seneviratne G, Howard L. Should we stop using tricyclic antidepressants in pregnancy? Psychol Med 2011;41(1):15-7.

1394. Nikfar S, Rahimi R, Hendoiee N, et al. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. Daru 2012;20(1):2008-231.

1395. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Bmj 2009;339:b3569.

1396. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40(10):1723-33.

1397. Colvin L, Slack-Smith L, Stanley FJ, et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011;91(3):142-52.

1398. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. Bmj 2015;350:h1798.

1399. BC Reproductive Mental Health Program, Perinatal Services. Best practice guidelines for mental health disorders in the perinatal period. Vancouver: BC Reproductive Mental Health Program; 2014. http://www.perinatalservicesbc.ca/Documents/Guidelines-Standards/Maternal/MentalHealthDisordersGuideline.pdf.

1400. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74(4):e293-e308.

1401. Myles N, Newall H, Ward H, et al. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 2013;47(11):1002-12.

1402. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159-70.

1403. Reefhuis J, Devine O, Friedman JM, et al. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. Bmj 2015;351:h3190.

1404. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf 2014;23(10):1066-75.

1405. Fenger-Gron J, Thomsen M, Andersen KS, et al. Paediatric outcomes following intrauterine exposure to serotonin reuptake inhibitors: a systematic review. Dan Med Bull 2011;58(9):A4303.

1406. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127(2):94-114.

1407. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182(10):1031-7.

1408. Huybrechts KF, Sanghani RS, Avorn J, et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One 2014;9(3):e92778.

1409. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry 2013;74(4):e309-e320.

1410. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013;70(4):436-43.

1411. Yonkers KA, Blackwell KA, Glover J, et al. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol 2014;10:369-92.

1412. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. Bmj 2012;344:d8012.

1413. Byatt N, Freeman MP. Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low. Evid Based Nurs 2015;18(1):15-6.

1414. Oyebode F, Rastogi A, Berrisford G, et al. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012;135(1):71-7.

1415. Palmsten K, Hernandez-Diaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. Bmj 2013;347:f4877.

1416. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf 2014;13(2):207-25.

1417. Berle JO, Spigset O. Antidepressant Use During Breastfeeding. Curr Womens Health Rev 2011;7(1):28-34.

1418. Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics 2009;124(4):2009-0326.

1419. Viguera AC, Newport DJ, Ritchie J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry 2007;164(2):342-5.

1420. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009;23(5):397-418.

1421. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68(11):1104-12.

1422. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. Bmj 2013;346:f2059.

1423. El Marroun H, White TJ, van der Knaap NJ, et al. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. Br J Psychiatry 2014;205(2):95-102.

1424. Sorensen MJ, Gronborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013;5(1):449-59.

1425. Howard LM, Hoffbrand S, Henshaw C, et al. Antidepressant prevention of postnatal depression. Cochrane Database Syst Rev 2005;CD004363.

1426. de Crescenzo F, Perelli F, Armando M, et al. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials. J Affect Disord 2014;152-154(1):39-44.

1427. Bloch M, Meiboom H, Lorberblatt M, et al. The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(2):235-41.

1428. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. Bmj 1997;314(7085):932-6.

1429. Sharp DJ, Chew-Graham C, Tylee A, et al. A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial. Health technology assessment 2010;14(43):1-153.

1430. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347(9006):930-3.

1431. Lawrie TA, Hofmeyr GJ, de Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol 1998;105(10):1082-90.

1432. Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev 2008;CD001690.

1433. Fitelson E, Kim S, Baker AS, et al. Treatment of postpartum depression: clinical, psychological and pharmacological options. Int J Womens Health 2010;3:1-14.

1434. Jans LA, Giltay EJ, Van der Does AJ. The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression. Br J Nutr 2010;104(11):1577-85.

1435. Dennis CL, Hodnett E. Psychosocial and psychological interventions for treating postpartum depression. Cochrane Database Syst Rev 2007;CD006116.

1436. Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003;160(3):555-62.

1437. Grote NK, Swartz HA, Geibel SL, et al. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv 2009;60(3):313-21.

1438. Spinelli MG, Endicott J, Leon AC, et al. A controlled clinical treatment trial of interpersonal psychotherapy for depressed pregnant women at 3 New York City sites. J Clin Psychiatry 2013;74(4):393-9.

1439. Dennis CL, Ross LE, Grigoriadis S. Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database Syst Rev 2007;CD006309.

1440. Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database Syst Rev 2013;CD001134.

1441. Sockol LE, Epperson CN, Barber JP. Preventing postpartum depression: a meta-analytic review. Clin Psychol Rev 2013;33(8):1205-17.

1442. Clatworthy J. The effectiveness of antenatal interventions to prevent postnatal depression in high-risk women. J Affect Disord 2012;137(1-3):25-34.

1443. Scope A, Leaviss J, Kaltenthaler E, et al. Is group cognitive behaviour therapy for postnatal depression evidence-based practice? A systematic review. BMC Psychiatry 2013;13:321.

1444. Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. Clin Psychol Rev 2011;31(5):839-49.

1445. Claridge AM. Efficacy of systemically oriented psychotherapies in the treatment of perinatal depression: a meta-analysis. Arch Womens Ment Health 2014;17(1):3-15.

1446. Miniati M, Callari A, Calugi S, et al. Interpersonal psychotherapy for postpartum depression: a systematic review. Arch Womens Ment Health 2014;17(4):257-68.

1447. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45(5):444-50.

1448. Leiknes KA, Cooke MJ, Jarosch-von Schweder L, et al. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health 2013;24:24.

1449. Melzer K, Schutz Y, Boulvain M, et al. Physical activity and pregnancy: cardiovascular adaptations, recommendations and pregnancy outcomes. Sports Med 2010;40(6):493-507.

1450. Nascimento SL, Surita FG, Cecatti JG. Physical exercise during pregnancy: a systematic review. Curr Opin Obstet Gynecol 2012;24(6):387-94.

1451. Daley A, Foster L, Long G, et al. The effectiveness of exercise for the prevention and treatment of antenatal depression: systematic review with meta-analysis. BJOG 2015;122(1):57-62.

1452. Perales M, Refoyo I, Coteron J, et al. Exercise during pregnancy attenuates prenatal depression: a randomized controlled trial. Eval Health Prof 2015;38(1):59-72.

1453. Daley A, Jolly K, MacArthur C. The effectiveness of exercise in the management of post-natal depression: systematic review and meta-analysis. Fam Pract 2009;26(2):154-62.

1454. Sado M, Ota E, Stickley A, et al. Hypnosis during pregnancy, childbirth, and the postnatal period for preventing postnatal depression. Cochrane Database Syst Rev 2012;CD009062.

1455. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371(9619):1200-10.

1456. Marjoribanks J, Brown J, O'Brien PM, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013;CD001396.

1457. Baker LJ, O'Brien PM. Premenstrual syndrome (PMS): a peri-menopausal perspective. Maturitas 2012;72(2):121-5.

1458. Nevatte T, O'Brien PM, Backstrom T, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013;16(4):279-91.

1459. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;CD006586.

1460. Ford O, Lethaby A, Roberts H, et al. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012;CD003415.

1461. Busse JW, Montori VM, Krasnik C, et al. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 2009;78(1):6-15.

1462. Judd FK, Hickey M, Bryant C. Depression and midlife: are we overpathologising the menopause? J Affect Disord 2012;136(3):199-211.

1463. Bromberger JT, Kravitz HM, Matthews K, et al. Predictors of first lifetime episodes of major depression in midlife women. Psychol Med 2009;39(1):55-64.

1464. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63(4):375-82.

1465. Freeman EW, Sammel MD, Boorman DW, et al. Longitudinal pattern of depressive symptoms around natural menopause. JAMA Psychiatry 2014;71(1):36-43.

1466. Vivian-Taylor J, Hickey M. Menopause and depression: is there a link? Maturitas 2014;79(2):142-6.

1467. Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: study of Women's Health Across the Nation (SWAN). Psychol Med 2011;41(9):1879-88.

1468. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63(4):385-90.

1469. Bromberger JT, di Scalea TL. Longitudinal associations between depression and functioning in midlife women. Maturitas 2009;64(3):145-59.

1470. Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health 2005;14(7):609-16.

1471. Pinto-Meza A, Usall J, Serrano-Blanco A, et al. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 2006;93(1-3):53-60.

1472. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001;9(4):393-9.

1473. Kornstein SG, Clayton A, Bao W, et al. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause 2014;21(8):799-806.

1474. Kornstein SG, Pedersen RD, Holland PJ, et al. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. J Clin Psychiatry 2014;75(1):62-8.

1475. Kornstein SG, Toups M, Rush AJ, et al. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. J Womens Health 2013;22(2):121-31.

1476. Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: A systematic review. J Am Assoc Nurse Pract 2014;19(10):2327-6924.

1477. Schmidt P. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19(3):257-71.

1478. Brandon AR, Minhajuddin A, Thase ME, et al. Impact of reproductive status and age on response of depressed women to cognitive therapy. J Womens Health 2013;22(1):58-66.

1479. Pöldinger W, Sonneck G. Die Abschätzung der Suizidalität. Nervenarzt 1980;51:147-51.

1480. Wolfersdorf MD. Der suizidale Patient in Klinik und Praxis. Suizidalität und Suizidprävention. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2000.

1481. Althaus D, Hegerl U. Ursachen, Diagnose und Therapie von Suizidalität. Nervenarzt 2004;75(11):1123-34.

1482. Skegg K. Self-harm. Lancet 2005;366(9495):1471-83.

1483. Fliege H. Pathologisch autodestruktives Verhalten und Verhaltenstherapie. Ein Überblick. Psychotherapeut 2002;47(4):193-203.

1484. Cheng AT. Mental illness and suicide. A case-control study in east Taiwan. Arch Gen Psychiatry 1995;52(7):594-603.

1485. Lönnqvist J. Psychiatric aspects of suicidal behaviour: depression. In: Hawton K, van Heeringen K, editors. The international handbook of suicide and attempted suicide. Chichester: Wiley; 2000.

1486. Lönnqvist JK, Henriksson MM, Isometsa ET, et al. Mental disorders and suicide prevention. Psychiatry Clin Neurosci 1995;49(1):S111-S116.

1487. Henriksson S, Boethius G, Isacsson G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985-95. Acta Psychiatr Scand 2001;103(4):301-6.

1488. Ministry of Health and Welfare. Suicide in Canada: update on national task force report on suicide. Ottawa: Health and Welfare Canada; 1994.

1489. Rudd MD. The assessment, management and treatment of suicidality: toward clinically informed and balanced standards of Care. Clin Psychol 1998;5(2):135-50.

1490. Silverman F, Berman A, Bongar B, et al. Inpatient standards of care and the suicidal patient. In: Bongar B, Berman AK, Maris RW, et al, editors. Risk management with suicidal patients. New York: Guilford Press; 1999.

1491. Malone KM, Oquendo MA, Haas GL, et al. Protective factors against suicidal acts in major depression: reasons for living. Am J Psychiatry 2000;157(7):1084-8.

1492. Blumenthal SJ, Kupfer DJ. Suicide over the life cycle: risk factors. Assessment and treatment of suicidal patients. Washington: American Psychiatric Publishing; 1990.

1493. Salkovskis PM, Atha C, Storer D. Cognitive-behavioural problem solving in the treatment of patients who repeatedly attempt suicide. A controlled trial. Br J Psychiatry 1990;157:871-6.

1494. Dicker R, Morrissey RF, Abikoff H, et al. Hospitalizing the suicidal adolescent: decision-making criteria of psychiatric residents. J Am Acad Child Adolesc Psychiatry 1997;36(6):769-76.

1495. Hawton K, Arensman E, Townsend E, et al. Deliberate self harm: systematic review of efficacy of psychosocial and pharmacological treatments in preventing repetition. Bmj 1998;317(7156):441-7.

1496. New South Wales Health Department (NSW). Policy guidelines for the management of patients with possible suicidal behaviour for NSW health staff and staff in private hospital facilities. Sydney: NSW Department of Health; 1998.

1497. Jacobson G. The inpatient management of suicidality. San Francisco: Josey-Bass; 1999.

1498. New Zealand Guidelines Group (NZGG), Ministry of Health. The assessment and management of people at risk of suicide. Best practice evidence-based guideline summary. Wellington: New Zealand Guidelines Group (NZGG); 2003. http://www.health.govt.nz/system/files/documents/publications/suicide_guideline.pdf.

1499. van der Sande R, van Rooijen L, Buskens E, et al. Intensive in-patient and community intervention versus routine care after attempted suicide. A randomised controlled intervention study. Br J Psychiatry 1997;171:35-41.

1500. Schneider F, Frister H, Olzen D. Begutachtung psychischer Störungen. Berlin: Springer; 2015.

1501. Storosum JG, van Zwieten BJ, van den Brink W, et al. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001;158(8):1271-5.

1502. Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007;164(7):1044-9.

1503. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009;180(3):291-7.

1504. Kamat MA, Edgar L, Niblock P, et al. Association between antidepressant prescribing and suicide rates in OECD countries: an ecological study. Pharmacopsychiatry 2014;47(1):18-21.

1505. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom Med 2003;72(2):71-9.

1506. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008;178(3):296-305.

1507. Donovan S, Kelleher MJ, Lambourn J, et al. The occurence of suicide following the prescription of antidepressant drugs. Arch Suicide Res 1999;5(3):181-92.

1508. Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. Bmj 2004;329(7456):34-8.

1509. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. Bmj 2005;330(7488):373-4.

1510. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. Bmj 2005;330(7488):389.

1511. Frey R, Schreinzer D, Stimpfl T, et al. Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 2000;10(2):133-42.

1512. Frey R, Schreinzer D, Stimpfl T, et al. Letale Intoxikationen mit Antidepressiva und Neuroleptika: Analyse im Zusammenhang mit den Verordnungen in Wien von 1991 bis 1997. Nervenarzt 2002;73(7):629-36.

1513. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96(5):369-74.

1514. Hegerl U. Antidepressiva und Suizidalität : Nutzen-Risiko-Abschätzung. Nervenarzt 2007;78(1):7-14.

1515. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. Jama 2003;290(11):1467-73.

1516. Pfennig A, Berghöfer A, Bauer M. Medikamentöse Behandlung der Suizidalität. Verhaltenstherapie 2005;15:29-37.

1517. Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 2001;65(2):173-7.

1518. Althaus D. Suizidprävention: Vorgehensweisen und Wirksamkeit. Verhaltenstherapie 2005;15(1):12-9.

1519. Brown GK, Bruce ML, Pearson JL. High-risk management guidelines for elderly suicidal patients in primary care settings. Int J Geriatr Psychiatry 2001;16(6):593-601.

1520. Henseler H. Krisenintervention. Stuttgart: Frommann-Holzboog; 1981.

1521. Crawford MJ, Thomas O, Khan N, et al. Psychosocial interventions following self-harm: systematic review of their efficacy in preventing suicide. Br J Psychiatry 2007;190(1):11-7.

1522. Mann JJ, Apter A, Bertolote J, et al. Suicide prevention strategies: a systematic review. Jama 2005;294(16):2064-74.

1523. Brown GK, Ten Have T, Henriques GR, et al. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. Jama 2005;294(5):563-70.

1524. Hawton K, McKeown S, Day A, et al. Evaluation of out-patient counselling compared with general practitioner care following overdoses. Psychol Med 1987;17(3):751-61.

1525. Gibbons JS, Butler J, Urwin P, et al. Evaluation of a social work service for self-poisoning patients. Br J Psychiatry 1978;133(2):111-8.

1526. McLeavey BC, Daly RJ, Ludgate JW, et al. Interpersonal problem-solving skills training in the treatment of self-poisoning patients. Suicide Life Threat Behav 1994;24(4):382-94.

1527. Evans MO, Morgan HG, Hayward A, et al. Crisis telephone consultation for deliberate self-harm patients: effects on repetition. Br J Psychiatry 1999;175(1):23-7.

1528. Guthrie E, Kapur N, Mackway-Jones K, et al. Randomised controlled trial of brief psychological intervention after deliberate self poisoning. Bmj 2001;323(7305):135-8.

1529. Hawton K, Townsend E, Arensman E, et al. Psychosocial versus pharmacological treatments for deliberate self harm. Cochrane Database Syst Rev 2000;CD001764.

1530. O'Connor E, Gaynes B, Burda BU, et al. Screening for Suicide Risk in Primary Care: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): 2013 [cited: 2016-09-14]. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0056019.

1531. Motto JA. Suicide prevention for high-risk persons who refuse treatment. Suicide Life Threat Behav 1976;6(4):223-30.

1532. Motto JA, Heilbron DC, Juster RP, et al. Communication as a suicide prevention program. Paris: Pergamon; 1981.

1533. de Leo D, Carollo G, Dello Buono M. Lower suicide rates associated with a Tele-Help/Tele-Check service for the elderly at home. Am J Psychiatry 1995;152(4):632-4.

1534. Morgan HG, Jones EM, Owen JH. Secondary prevention of non-fatal deliberate self-harm. The green card study. Br J Psychiatry 1993;163:111-2.

1535. Appleby L, Shaw J, Amos T, et al. Suicide within 12 months of contact with mental health services: national clinical survey. Bmj 1999;318(7193):1235-9.

1536. Brown TM, Scott AIF. Handbook of emergency psychiatry. New York: Churchill Livingstone; 1990.

1537. Motto JA, Bostrom AG. A randomized controlled trial of postcrisis suicide prevention. Psychiatr Serv 2001;52(6):828-33.

1538. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Evidenzbericht Suizidalität unter Berücksichtigung der Depression. Berlin: ÄZQ; 2005.

1539. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974;7(0):151-69.

1540. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136(10):765-76.

1541. Williams JW, Jr., Noel PH, Cordes JA, et al. Is this patient clinically depressed? Jama 2002;287(9):1160-70.

1542. Hiroe T, Kojima M, Yamamoto I, et al. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res 2005;135(3):229-35.

1543. Brähler E, Schumacher J, Strauß B. Diagnostische Verfahren in der Psychotherapie. Göttingen: Hogrefe; 2002.

1544. Brähler E, Holling H, Leutner D, et al. Handbuch Psychologischer und Pädagogischer Tests. Göttingen: Hogrefe; 2002.

1545. Bauer M, Grof P, Müller-Oerlinghausen B. Lithium in neuropsychiatry - the comprehensive guide. London: Informa Healthcare; 2006.

1546. Müller-Oerlinghausen B, Berghöfer A, Greil W. Die Lithiumtherapie. Berlin: Springer; 1997.


Zurück zum Anhang

zuletzt verändert: 15.06.2017 12:43